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ABSTRACT 
Cardiogenic shock (CS) is a medical emergency in which cardiac dysfunction 
causes a state of shock resulting in end-organ hypoperfusion. The most 
common cause of CS is acute coronary syndrome (ACS), ST-segment elevation 
myocardial infarction (STEMI) being the leading aetiology. Other causes of CS 
may include exacerbation of chronic heart failure, valvular dysfunction, 
myocarditis, and stress-induced cardiomyopathy. Despite progress in 
revascularization and development of mechanical circulatory support-devices, 
short-term mortality is still high at 40%, which calls for further advances in 
CS management and in risk stratification. 
The electrocardiogram (ECG) plays a major role at the first instance of 
CS management, as it provides essential information about cardiac ischaemia, 
rhythm, and conduction. After initial evaluation, emergent coronary 
angiography is the next step in CS management with the possibility of 
immediate revascularization with percutaneous coronary intervention (PCI). 
The aim of this study was to examine electrocardiographic and angiographic 
features in CS. The patient data in this thesis are primarily included in a 
multinational, prospective, observational cohort study called the CardShock 
study, which investigated 219 CS patients with diverse CS aetiologies. 
Study I evaluated baseline ECG ST-segment patterns in patients with 
differing CS aetiologies. ST-segment elevation was associated with ACS, and 
in patients with ST-segment elevation, CS was often the first manifestation of 
coronary artery disease. One-third of patients with ST-segment depression did 
not have ACS, but ST-segment depression was associated with a high burden 
of previous comorbidities. ST-segment elevation was associated with 90-day 
mortality in patients with mixed CS aetiologies. In the subgroup of ACS 
patients, no difference in revascularization or mortality rates emerged 
between the studied ST-segment patterns. 
Study II examined ventricular conduction disturbances in patients with 
ACS-related CS. In this population, ventricular conduction disturbances 
occurred more often in older patients with a higher burden of comorbidities. 
The temporal evolution of ventricular conduction blocks from baseline to day 
three was high, because one-third of the blocks were transient. All ventricular 
conduction disturbances were associated with poor prognosis, and the 
reversal of the block during the first three days was not associated with better 
one-year survival. 
Study III examined the prognostic value of the SYNTAX scores in 
STEMI-related CS patients. The SYNTAX score is a tool created for 
assessment of the complexity of coronary artery disease. In this study, 
SYNTAX score was calculated before PCI (baseline SYNTAX score) and after 
PCI (residual SYNTAX score). The baseline SYNTAX score was associated 
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with mortality, but its additive value in risk prediction beyond clinical 
assessment and risk scores was marginal. Residual SYNTAX score did not 
associate with outcome in STEMI-related CS. 
Study IV examined angiographic features and their prognostic value in 
ACS-related CS. Multivessel disease and unsuccessful revascularization of the 
infarct-related artery were associated with poor prognosis. In addition, 
assessment of procedural PCI complications showed that arrhythmic 
complications were the most common, but they did not associate with worse 
outcome. 
In conclusion, electrocardiography is an important tool for 
differentiating the aetiologies of CS and it can be useful in risk assessment. 
ST-segment elevation and ventricular conduction blocks are markers of high 
mortality risk. In addition, some angiographic features may prove useful in 
prognosis assessment. Multivessel disease carries a high mortality risk, 
whereas successful revascularization of the infarct-related artery is associated 
with better outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 
 
TIIVISTELMÄ 
Sydänperäinen shokki on lääketieteellinen hätätilanne, jossa äkillinen 
sydämen vajaatoiminta aiheuttaa elimistön yleisen shokkitilan ja 
verenkierron vajauksen. Sepelvaltimotautikohtaus on yleisin sydänperäisen 
shokin aiheuttaja. Useimmiten potilaalla todetaan ST-nousuinfarkti. 
Sydänperäisen shokin muita syitä voivat olla kroonisen sydämen 
vajaatoiminnan pahenemisvaihe, sydänläppien viat, sydänlihastulehdus tai 
järkytyksen aiheuttama sydänhalvaus. Sydänperäisen shokin hoitomuotojen 
kehityksestä huolimatta sairauden kuolleisuus on korkea, sillä jopa puolet 
potilaista menehtyy sairaalahoidon aikana. Sydänperäisen shokin huono 
ennuste peräänkuuluttaakin edistysaskelia sydänperäisen shokin hoidossa ja 
riskin arviossa. 
 Sydänsähkökäyrä on keskeinen työkalu sydänperäisen shokin 
diagnostiikassa ensihetkistä lähtien. Sydänsähkökäyrä antaa tietoa 
sydänlihaksen hapenpuutteesta ja mahdollisista rytmi- ja johtumishäiriöistä. 
Ensiarvion jälkeen kaikille sydänperäistä shokkia sairastaville potilaille tulisi 
tehdä kiireellinen sepelvaltimoiden varjoainetutkimus. 
Varjoainetutkimuksessa voidaan todeta tukkeutunut sepelvaltimo ja hoitaa se 
pallolaajennuksella. Tämän väitöskirjan tavoitteena on tutkia neljässä eri 
osatyössä sydänsähkökäyrän muutoksia ja sepelvaltimoiden 
varjoainetutkimuksen löydöksiä sydänperäisessä shokissa. Väitöskirjan 
potilasmateriaali on pääosin peräisin 219 potilaan CardShock tutkimuksesta, 
joka on sydänperäisen shokin etenevä ja havainnoiva monikeskustutkimus.  
Osatyössä I tutkittiin sisäänottovaiheen sydänsähkökäyrien ST-tasojen 
muutoksia. ST-nousupotilailla sepelvaltimotautikohtaus oli yleisimmin 
shokin aiheuttaja ja sydänperäinen shokki oli usein sepelvaltimotaudin 
ensimmäinen ilmentymä. Yhdellä kolmasosalla ST-laskupotilaista shokin syy 
oli muu kuin sepelvaltimotautikohtaus. ST-lasku oli kuitenkin yhteydessä 
suurempaan todennäköisyyteen sairastaa liitännäissairauksia. Koko 
tutkimuskohortissa ST-nousu oli yhteydessä huonoon ennusteeseen. 
Sepelvaltimotautikohtauspotilaat hoidettiin pallolaajennuksella yhtä usein 
ST-tason muutoksista huolimatta, eikä eroa kuolleisuudessa todettu. 
 Osatyössä II arvioitiin kammiojohtumisen häiriöitä potilailla, joilla oli 
sepelvaltimotautikohtauksesta johtuva sydänperäinen shokki. 
Kammiojohtumisen häiriöt olivat yleisiä ja ne olivat yhteydessä korkeampaan 
ikään ja suurempaan riskiin sairastaa liitännäissairauksia. 
Kammiojohtumisen häiriöt olivat usein ohimeneviä, sillä jopa puolet 
todetuista kammiojohtumisen häiriöistä hävisivät tai muuttuivat toiseksi 
häiriöksi kolmen päivän seurannan aikana. Kammiojohtumisen häiriöt 
liittyivät huonompaan ennusteeseen, sillä kaikki eri kammiojohtumisen 
häiriön muodot olivat yhteydessä korkeampaan kuolleisuuteen, eikä 
myöhempi johtumisen korjaantuminen parantanut ennustetta. 
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 Osatyössä III selvitettiin SYNTAX scoren ennusteellista merkitystä ST-
nousuinfarktin aiheuttamassa sydänperäisessä shokissa. SYNTAX score on 
työkalu, jolla voidaan arvioida sepelvaltimotaudin vaikeusastetta. Tässä 
tutkimuksessa SYNTAX score laskettiin ennen sepelvaltimoiden 
pallolaajennusta (baseline SYNTAX score) ja pallolaajennuksen jälkeen 
(residual SYNTAX score). Baseline SYNTAX score oli yhteydessä 
korkeampaan kuolleisuuteen, mutta sen tuoma lisäarvo riskinarviossa 
kliinisten tekijöiden ja riskilaskureiden ohella oli rajallinen. Residual 
SYNTAX scorella ei ollut merkitystä ennusteen arviossa. 
 Osatyössä IV selvitettiin sepelvaltimoiden varjoainekuvauksen 
löydösten ennusteellista merkitystä sepelvaltimotautikohtauksen 
aiheuttamassa sydänperäisessä shokissa. Monisuonitauti ja epäonnistunut 
verenkierron palautuminen pallolaajennuksen jälkeen liittyivät huonoon 
ennusteeseen. Lisäksi tutkittiin pallolaajennuksen aikaisia komplikaatioita, 
joista rytmihäiriöt olivat yleisimpiä; niiden esiintyminen ei kuitenkaan 
huonontanut ennustetta.  
Yhteenvetona voidaan todeta, että sydänsähkökäyrä on tärkeä 
työväline sydänperäisen shokin aiheuttajan ja ennusteen arvioinnissa. ST-
nousu ja kammiojohtumisen häiriöt ovat yhteydessä korkeaan kuolleisuuteen. 
Sepelvaltimoiden varjoainekuvauksen löydöksistä osa on hyödyllisiä 
sydänperäisen shokin ennusteen arvioinnissa. Monisuonitauti on huonon 
ennusteen merkki, kun taas onnistunut verenkierron palautuminen 
pallolaajennuksen yhteydessä on yhteydessä parempaan ennusteeseen.  
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1 INTRODUCTION 
Cardiogenic shock (CS) is a medical emergency in which cardiac dysfunction 
causes a state of shock resulting in end-organ hypoperfusion. The most 
common aetiology of CS is acute coronary syndrome (ACS) (1,2). Other causes 
include exacerbation of chronic heart failure, valvular dysfunction, stress-
induced cardiomyopathy, and myocarditis (3).  In the last four decades, short-
term mortality rates of CS have decreased from 80% to the current 40% 
(1,4,5), mainly due to increased use of revascularization strategies. Despite 
progress in reperfusion therapies and in modern intensive care, in-hospital 
mortality is still unacceptably high, and advances in management and risk 
stratification are necessary. 
The electrocardiogram (ECG) is an important diagnostic tool in CS. In 
an acute setting, ST-segment deviations, i.e. ST-segment elevation (STE) and 
ST-segment depression (STDEP), often raise the idea of myocardial ischaemia 
and acute myocardial infarction. ST-segment deviations can, however, also be 
chronic changes resulting from left ventricular hypertrophy (6), or be acute 
changes resulting from other cardiac diseases such as myocarditis or stress-
induced cardiomyopathy (7,8). In CS patients, ST-segment deviations have 
only been studied in the context of ACS, mostly by dividing patients into two 
established categories: ST-segment elevation myocardial infarction (STEMI) 
or non-ST-segment elevation myocardial infarction (NSTEMI). Separate data 
on patients with STE and STDEP and on patients without ST-segment changes 
(NSTD), are, however, scarce. ST-segment deviations, in particular, have not 
been studied in patients with CS aetiologies other than ACS.  
In addition to ST-segment levels, analysis of QRS configuration and 
duration is important in patients with acute cardiac distress, because acute 
changes in the QRS complex may be attributable to severe myocardial 
ischaemia (9). In ACS, bundle branch block in the baseline ECG has been 
associated with high incidence of CS (10–13) and with increased short- and 
long-term mortality (11,12,14–16). In the context of myocardial ischaemia, 
conduction disturbances are often transient (17,18), with a high frequency of 
block resolution being described in patients with ACS (16,19). Previously, 
resolution of ventricular conduction disturbances has been associated with 
better outcome (12,16). A few studies in CS patients have shown that 
prolonged QRS (20) and right bundle branch block (RBBB) are associated 
with worse survival (11,21), but other ventricular conduction disturbances 
such as fascicular hemiblocks and unspecified intraventricular conduction 
delay (IVCD), and temporal evolution of the ventricular conduction blocks, 
have been neglected in the context of ACS-related CS. 
Because ACS is the most common aetiology of CS, emergent coronary 
angiography and revascularization are essential in CS management. In 
addition to treatment with percutaneous coronary intervention (PCI), 
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coronary angiography provides information about coronary anatomy and the 
extent of coronary artery disease. Previously in ACS-related CS, multivessel- 
(22–24) and three-vessel coronary artery disease (25–28), left main (LM) 
coronary artery as the infarct-related artery (IRA) (23,25,27), and 
unsuccessful revascularization of the IRA (23–25,27–31) have been 
associated with worse outcome. Many of these studies, however, predated the 
primary PCI era (25–27), were of a retrospective design (30,32), or examined 
registry data (23,28,31).  Complications during PCI in patients with ACS are 
fairly common (33), but data are scarce on procedural complications and on 
their effect on outcome in ACS-related CS.   
The SYNTAX score is an angiographic scoring tool calculated from 
coronary angiograms defining the extent of coronary artery disease. The 
baseline SYNTAX score is calculated before PCI, and it reflects the burden of 
coronary artery disease. The residual SYNTAX score is calculated after PCI 
and can serve as a tool to evaluate completeness of revascularization. Both 
SYNTAX scores have been associated with outcome in patients with ACS (34–
39), but they have not been studied in CS.  
The aim of this thesis is to study electrocardiographic changes and 
features of coronary angiography in CS patients primarily included in a 
prospective, observational, multinational study of CS called the CardShock 
study.  
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2 REVIEW OF THE LITERATURE 
2.1 Cardiogenic shock 
2.1.1 Diagnosis and classification 
Cardiogenic shock (CS) is the most severe form of heart failure, a state of 
inadequate tissue- and end-organ perfusion resulting from primary cardiac 
dysfunction (40). Diagnostic criteria for CS include persistent hypotension 
unresponsive to volume replacement (systolic blood pressure [SBP] ?? 90 
mmHg) in combination with clinical hypoperfusion (cold extremities, 
oliguria, mental confusion, dizziness, and narrow pulse pressure) (41). 
Laboratory measures associated with hypoperfusion are metabolic acidosis, 
elevated serum lactate, and elevated serum creatinine (41).  
Though CS diagnosis is based on clinical findings, objective invasive 
haemodynamic parameters can serve in confirming the diagnosis. The 
Forrester classification of acute heart failure was developed in patients with 
acute myocardial infarction, categorising patients into four haemodynamic 
groups by measurements of cardiac index and pulmonary capillary wedge 
pressure (PCWP) (Figure 1) (42). The classification of acute heart failure can 
also be made without invasive testing, based on bedside physical examination. 
The aim is to detect the presence of clinical signs of congestion (‘wet’ vs. ‘dry’) 
and peripheral hypoperfusion (‘cold’ vs. ‘warm’) (41,43). In classic CS, the 
cardiac index is low (< 2.2 L/min/m2), PCWP is elevated (> 18 mmHg), and 
systemic vascular resistance is high, clinically corresponding to the ‘wet’ and 
‘cold’ profile (3,42). Figure 2 describes other haemodynamic phenotypes of 
CS, in which a low cardiac index is present in them all, but ventricular preload, 
volume, and systemic vascular resistance may vary (3). A haemodynamically 
distinct entity is right ventricular CS, in which patients can be normotensive 
with peripheral hypoperfusion, haemodynamically characterized by relatively 
higher central venous pressures, higher left ventricular ejection fraction 
(LVEF), and lower pulmonary artery systolic pressures, with no difference in 
PCWP (3). 
The clinical manifestation of CS at presentation ranges from mild 
hypoperfusion to profound shock and a pulseless state (44). Refractory CS can 
be defined as ongoing evidence of tissue hypoperfusion despite administration 
of adequate doses of two vasoactive medications and appropriate treatment of 
the underlying aetiology (45). 
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Figure 1  Forrester classification of heart failure. H I-IV refers to haemodynamic 
  severity, C I-IV refers to clinical severity. Abbreviations: CI = cardiac 
  index, PCWP = pulmonary capillary wedge pressure. Reproduced with 
  the permission of Oxford Academics (46). 
 
 
 
 
 
 
 
 
 
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000525 
 
 
Figure 2 Haemodynamic presentations of cardiogenic shock. Abbreviations: CI 
  = cardiac index, PCWP = pulmonary capillary wedge pressure, SVRI = 
  systemic vascular resistance index. Reproduced with the permission 
  of Wolters Kluwer (3). 
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2.1.2 Aetiology 
Acute cardiac haemodynamic instability can result from disorders worsening 
the function of the myocardium, valves, conduction system, or pericardium, 
either in isolation or in combination. The most common aetiology is acute 
coronary syndrome (ACS) in 50% to 80% of the cases (2,47). ACS is due to 
decreased blood flow in the coronary arteries, resulting in myocardial 
ischaemia and myocardial infarction. Type 1 myocardial infarction results 
from atherothrombotic coronary artery disease and is usually precipitated by 
atherosclerotic plaque disruption. Type 2 myocardial infarction results from 
the imbalance of oxygen supply and demand in the myocardium (48). The 
three main clinical manifestations of ACS defined by electrocardiographic 
findings are STEMI, NSTEMI, and unstable angina. ACS diagnosis is based on 
symptoms, electrocardiographic findings, troponin elevations, and imaging. 
In CS, STEMI predominates as the main cause, followed by NSTEMI (1,2). In 
the context of ACS, the cause of CS can also be a mechanical complication, 
such as rupture of a papillary muscle, of the ventricular septum, or of the 
ventricular free wall (40). In addition, acute severe mitral regurgitation, 
caused by papillary muscle dysfunction due to papillary muscle ischaemia, can 
be the cause of CS (46).  
The second most common cause of CS is exacerbation of chronic heart 
failure (3). Other, more rare causes are for example valvular dysfunction, 
myocarditis, stress-induced cardiomyopathy, pulmonary embolism, peri-
partum cardiomyopathy, cardiac tamponade, cardiac constriction, or dynamic 
outflow tract obstruction. In addition, CS can be iatrogenic, caused by 
excessive or too-early treatment with beta-blockers or angiotensin-converting 
enzyme inhibitors or by excess volume loading in right ventricular failure (40). 
2.1.3 Pathophysiology 
CS is a result of temporary or permanent haemodynamic disturbances in the 
heart and in the entire circulatory system. Depressed myocardial contractility 
results in a detrimental vicious cycle of reduced cardiac output, low blood 
pressure, and reduced flow in the coronary arteries, all leading to further 
coronary ischaemia and additional reduction in myocardial contractility (40). 
Myocardial stunning is a phenomenon resulting from an episode of intense 
ischaemia and subsequent reperfusion. This condition is characterized by a 
post-ischaemic perfusion-contraction mismatch in which contractile function 
remains severely depressed despite normal myocardial blood flow (49). 
Myocardial stunning is regarded as reversible, but in patients with myocardial 
infarction, it can contribute to the development of CS. In addition to 
myocardial stunning, evidence exists of vascular, metabolic, neuronal, and 
electrical stunning in the post-ischaemic phase (50). In addition, decreased 
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left ventricular function and myocardial ischaemia causes deterioration of 
diastolic function, leading to elevation in left arterial pressure and 
consequently to pulmonary congestion, hypoxia, and worsening ischaemia 
(45).   
The cascade of worsening systolic and diastolic dysfunction provokes 
compensatory mechanisms that are often maladaptive and further lead to a 
progressive downward spiral of worsening shock. The compensatory 
mechanisms include systemic vasoconstriction that may initially improve 
coronary and peripheral perfusion, but subsequently causes increased cardiac 
afterload, which overburdens the already damaged myocardium (51). 
Hypoperfusion causes activation of the sympathetic system, i.e. the release of 
catecholamines, which improves myocardial contractility and peripheral 
blood flow, but also causes increased myocardial oxygen demand and has 
proarrhythmogenic effects (40). Activation of compensatory neurohormonal 
responses leads to upregulation of the renin-angiotensin system, which causes 
increased preload, systemic vasoconstriction, and fluid retention (52). In 
addition, inflammatory response mechanisms are stimulated, resulting in the 
release and activation of inducible nitric oxide synthase and peroxynitrite, 
which stimulate pathological vasodilatation and have cardiotoxic and negative 
inotropic effects (53–56). Furthermore, increased levels of interleukins have 
been associated with higher mortality (57). And, extensive inflammatory 
response, even without concomitant infection, is associated with worse CS 
outcome (58). Taking into account the complexity of CS mechanisms, it is not 
surprising that severe impairment of left ventricular contractility does not 
always cause CS, and conversely, in CS, LVEF may only be moderately 
depressed, for example in those with acute aortic or mitral regurgitation (59).  
2.1.4 Epidemiology 
In the context of ACS, CS incidence ranges from 3% to 14% (4,10,31,60–64). 
This relatively wide range reflects different CS definitions, different patient 
profiles, and different time periods, and no clear tendency towards increase or 
decrease in CS incidence emerges in these studies. In the majority of ACS 
patients, CS is not present at hospital admission; it occurs most often during 
the first 24 hours of hospitalisation (1,10,60,61). ACS patients who develop 
CS are older and more often female. They also have more comorbidities and 
more often suffer from anterior myocardial infarction when compared to ACS 
patients without CS (62,64–66). In acute heart failure, CS incidence ranges 
from 2% to 7% (67–71); data on other CS aetiologies are scarce. The incidence 
of CS in stress-induced cardiomyopathy is reportedly around 10% (72–74). 
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2.1.5 Prognosis 
Within four decades, short-term mortality rates in CS have decreased from 
80% to the current 35% to 50% (1,4,31,61,71,75,76). Development of medical 
treatment and especially introduction of revascularization strategies have 
been key components in improvement of CS prognosis up to the beginning of 
the 21st century (77). Regardless of improved revascularization strategies and 
the introduction of mechanical support devices, no substantial decline in 
mortality rates has, however, been evident during the past 15 years (1,31). In 
general, mortality rates in CS are highest during hospitalisation (31,78). After 
hospital discharge, the mortality rates from CS in comparison to those from 
ACS were higher up to 60 days, but thereafter survival rates were similar (79). 
Indeed, if a CS patient survives from the acute phase, long‐term survival 
approximates  that of ACS patients without CS (80).  
Several biological and clinical factors are under study for prognosis 
assessment in CS. Risk stratification tools incorporate these factors into risk 
scores. The GRACE risk score, which includes eight predictors of death and 
was developed for patients with ACS,  has good discrimination for in-hospital 
and long-term mortality, but is not applicable to CS patients without ACS 
(81,82). Two risk-prediction tools for in-hospital mortality in CS have been 
derived from randomized trials of CS: the Sleeper score from the SHOCK 
(SHould we emergently revascularize Occluded Coronaries for cardiogenic 
shock) trial cohort including eight items (83) and the IABP-SHOCK II risk 
score from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic 
Shock II) trial cohort with six items (84). In addition, we present in detail a 
risk score created from the CardShock Study population (85), in the methods 
section. Table 1 describes the factors included in the above-mentioned risk 
scores. 
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Table 1  Clinical covariates included in different risk scores  
 
 
 
Abbreviations: ACS = acute coronary syndrome, CABG = coronary artery bypass 
grafting, CS = cardiogenic shock, ECG = electrocardiogram, eGFR = estimated 
glomerular filtration rate, LVEF = left ventricular ejection fraction, PCI = 
percutaneous coronary intervention, SBP = systolic blood pressure, STE = ST-segment 
elevation 
 
GRACE 
2003 
Sleeper 
2010 
CardShock 
2015 
IABP-SHOCK II 
2017 
Higher age x x x x 
ACS aetiology for CS   x  
Systolic blood pressure x x  
 
Heart rate x 
 
 
 
Arterial lactate 
  
x x 
Glucose (> 10.6 mmol/L or 191 mg/dL) 
  
 x 
Creatinine or eGFR x x x x 
LVEF   x  
Cardiac arrest at admission x 
 
 
 
STE on ECG x 
 
 
 
Abnormal cardiac enzymes/markers x 
 
 
 
Killip class x 
 
 
 
Shock on admission 
 
x  
 
Clinical signs of end-organ 
hypoperfusion 
 
x  
 
Anoxic brain damage / confusion  
 
x x 
 
Prior myocardial infarction/CABG 
 
x x 
 
Non-inferior myocardial infarction 
 
x  
 
Prior stroke 
  
 x 
TIMI < 3 flow post-PCI 
  
 x 
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2.2 Management of cardiogenic shock 
2.2.1 Initial evaluation and patient monitoring 
Patients with suspected CS should undergo immediate comprehensive 
assessment (41). The electrocardiogram (ECG) is the first tool to discriminate 
between myocardial ischaemia and other possible CS causes such as 
conduction disturbances (3,86). Echocardiography is required immediately, 
primarily for evaluation of left and right ventricular function, for valve 
dysfunction, and also for possible diagnosis of mechanical complications of 
ACS (44). If ACS is suspected, immediate coronary angiography is 
recommended, and in the case of mechanical complication, immediate 
surgical treatment is indicated (87). All CS patients should be transferred to a 
tertiary care center, with 24/7 service of cardiac catheterization and a 
dedicated intensive or cardiac care unit with a possibility of short-term 
mechanical circulatory support (41).  
Continuous telemetry, arterial blood pressure monitoring, and central-
vein pressure monitoring are suggested (3), but with no clear evidence for the 
optimal method of  haemodynamic monitoring (41). Randomized studies and 
meta-analyses have failed to show the benefit in using a pulmonary artery 
catheter in critically ill patients (88–90). Based on recommendations of CS 
management, the pulmonary artery catheter is not a routine recommendation, 
but it is an option in selected patients with severe CS (3,41,44). In general, 
evaluation of the adequacy of end-organ and tissue perfusion requires 
integrating serial markers of systemic perfusion, which include arterial 
lactate, mixed or central venous oxygen saturations, urine output, creatinine, 
liver-function tests, mental status, temperature, and invasive haemodynamic 
variables, including pulmonary artery catheter measurements, especially if 
initial therapy is unsuccessful (3). 
2.2.2 Haemodynamic management and vasoactive medications 
In CS, at least relative hypovolemia is common. The first line of treatment of 
hypotension is fluid challenge (> 200 ml of fluid within 15-20 minutes) to 
correct hypovolemia and to optimize right ventricular preload in order to 
elevate cardiac output, especially if no overt fluid overload is present 
(41,91,92) Setting one target limit for mean arterial pressure (MAP) is 
challenging, since CS is a haemodynamically heterogeneous disorder in which 
haemodynamic measurements may not adequately reflect end-organ blood 
flow or tissue perfusion (3). An initial target for MAP of over 65 to 70 mmHg 
is what most experts consider adequate (93). Unless fluid therapy corrects the 
haemodynamic instability, vasoactive treatment should be commenced to 
restore adequate perfusion pressure and cardiac output. 
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The most used vasopressors are catecholamines, which act through 
adrenergic α and β receptors. In the current guidelines, noradrenaline is the 
choice over dopamine (3,41), since some evidence exists that noradrenaline 
may be associated with better outcome in shock patients, dopamine being 
associated with a higher rate of arrhythmias (94). Use of adrenaline is only 
reserved for resuscitation and may be considered in refractory shock (41), 
because adrenaline may be associated with excess CS mortality (95–97). 
Although necessary for optimization of haemodynamic instability, 
catecholamines produce adverse effects. They cause vasoconstriction, which 
may worsen myocardial ischaemia and impair tissue microcirculation. In 
addition, catecholamines elevate the demand for myocardial oxygen and can 
trigger arrhythmias (98,99). All efforts are essential to minimize vasoactive 
medications; all of  them should be administered at the lowest dose and for 
the shortest period possible (45). 
Another type of vasoactive medications comprises inotropic agents, 
whose role is to enhance myocardial contractility and vasodilatation. 
Dobutamine is the most commonly recommended inotrope (41,44), a 
synthetic catecholamine with its predominant effect via β1 stimulation, 
resulting in increased heart rate and contractility (99). Levosimendan is a 
calcium sensitizer, which induces inotropy by calcium sensitization of 
contractile proteins in the cardiac myocytes (100). A recent Cochrane review 
of 13 trials showed that levosimendan may result in better short-term 
outcome than dobutamine but found no evidence of long-term benefit (101). 
Milnirone is a PDE3 inhibitor that raises intracellular cAMP and thus has 
inotropic effects independent of those of ? receptors. One retrospective study 
comparing dobutamine and milrinone found no differences between them in 
haemodynamic changes or in the extent of the resultant hypotension, whereas 
the use of concomitant vasoactive medications was similar between the 
groups. Milrinone was more often discontinued because of hypotension, and 
dobutamine because of arrhythmia (102). 
2.2.3 Mechanical circulatory support  
In refractory CS, mechanical circulatory support (MCS) may be considered to 
improve haemodynamics, to maintain adequate perfusion pressure and to 
prevent multiorgan failure. Previously, the intra-aortic balloon pump (IABP) 
was the most widely used MCS in CS in up to 45% of ACS-related CS patients 
(1,61,103) and even in 82% of the patients in refractory shock (104). 
International recommendations for IABP utilization were, however, 
downgraded after publication of the IABP-SHOCK II trial, which showed no 
survival benefit with IABP in ACS-related CS, either  in short- or in long-term 
follow-up (105–107). A recent Cochrane review also found similar results 
(108). Currently, IABP is not routinely recommended for CS, but may be 
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considered for haemodynamic support in selected patients, for example in the 
context of a mechanical complication of myocardial infarction (41,109).  
Other MCS include left ventricular assist devices (LVAD) and 
extracorporeal circulatory support. With the lack of IABP benefit, the rate of 
active MCS use has increased (2). In theory, MCS can permit haemodynamic 
stabilization, which may interrupt the vicious spiral of hypotension, 
myocardial dysfunction, and myocardial ischaemia (110). One hypothesis is, 
however, that the artificial contact with these devices in fact promotes 
systemic inflammatory response (3). In addition, bleeding complications are 
common with MCS (111). A recent meta-analysis including four randomized 
trials  showed no improvement in mortality with the use of an LVAD versus 
an IABP (111). Current guidelines recommend that MCS may only be 
considered in refractory shock (109). Indeed, MCS utilization relies mainly on 
individual experience of dedicated centres in carefully selected patients and 
each MCS application should be a decision of a multidisciplinary team (112).  
Extracorporeal circulatory support devices such as veno-arterial 
extracorporeal membrane oxygenation (va-ECMO) has good potential in CS, 
since it offers both cardiac and respiratory support (110). Small studies have 
described increased CS survival with the use of an ECMO in comparison with 
an IABP (113), but not with an LVAD (114,115). A clinical problem with using 
ECMO in CS is the marked increase in left ventricular afterload, causing 
pulmonary oedema, left ventricular dilation, stasis, and finally thrombus 
formation (116). To overcome this complication, some centres have begun the 
combined use of ECMO and LVAD (117,118). 
2.3 Coronary angiography and revascularization in cardiogenic shock 
2.3.1 Extent of coronary artery disease 
The blood supply to the myocardium is provided by the three main coronary 
arteries. The right coronary (RCA) artery originates directly from the root of 
the aorta, as does the left main (LM) coronary artery. The LM coronary artery 
then divides into its two main branches called the left anterior descending 
coronary artery (LAD) and the left circumflex artery (LCX). The LAD supplies 
the anterolateral myocardium, apex, and interventricular septum. The LCX 
supplies the posterolateral ventricle, and the RCA supplies the right ventricle 
and the posterior wall of the left ventricle, but the territories of the LCX and 
RCA may differ, due to the dominance of either vessel. A significant coronary 
obstruction is defined as ≥ 50% angiographic diameter stenosis in the 
epicardial coronary arteries (119). 
The majority of CS patients have multivessel coronary artery disease 
(22–28,120–122), a condition associated with higher mortality than one-
vessel disease (22,23,25–28). The percentages of the infarct-related arteries 
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(IRAs) have been reported as the following: LM in approximately 6%, LAD in 
40%, LCX in 10% to 15%, RCA in  30% to 40%, and a bypass graft in 2% to 8% 
(23,25,27). The LM as the IRA has been associated with poor outcomes 
(23,25,27,31), whereas the RCA has been associated with better survival 
(26,32). One study reported no difference in mortality between different 
culprit arteries, but showed that distal lesions were associated with higher 
mortality than were proximal lesions (24). In addition, chronic total occlusion 
in a non-IRA has been associated with poor outcomes (22,123–125). 
2.3.3 Fibrinolytic therapy 
Data on fibrinolysis in CS is limited, and the few studies have found no 
mortality benefit from thrombolytic therapy versus placebo (126). In a 
subgroup analysis of a STEMI trial called the GUSTO I (The Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries), no mortality benefit was discovered between fibrinolytic strategies 
in CS, but PCI was associated with a lower mortality rate (127). Animal studies 
have suggested that the performance of thrombolytic therapies may be 
dependent on perfusion pressure and coronary blood flow (128), a reason why 
their benefit in CS patients may be limited. However, expert 
recommendations state that fibrinolysis may be considered in STEMI-related 
CS, if early invasive treatment is impossible in an adequate time (3,44). 
2.3.4 Early revascularization 
Current guidelines (41,87,109,129) recommend early revascularization in 
patients with ACS-related CS. The landmark SHOCK trial compared early 
revascularization and initial medical stabilization. It failed to prove survival 
benefit in the primary end-point at 30 days (130), but showed that early 
revascularization was associated with lower 6-month, and 1- and 6-year 
mortality (130,131). Another trial conducted in the same era, the (Swiss) 
Multicenter Trial of Angioplasty for Shock,  (S)MASH, was unable to prove the 
survival benefit of early revascularization when compared to that of initial 
medical treatment, but significant problems arose with patient recruitment, 
since only 55 patients were randomized (132). A recent registry study from 
the USA compared conservative versus invasive management of patients with 
ACS-related CS and found lower in-hospital mortality in patients with invasive 
management (38% vs 60%) (133). A recent large registry study found that lack 
of PCI was independently associated with higher in-hospital mortality (5). In 
registry studies, an early revascularization strategy has been applied to 45% to 
88% of the CS patients with increasing rates in recent years 
(4,5,10,28,60,63,65,134,135).   
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2.3.5 Time-to-revascularization 
Time-to-revascularization has only been studied in STEMI-related CS 
patients. The FITT-STEMI trial showed the importance of prompt 
revascularization by investigating first medical contact to balloon time in 
patients with STEMI-related CS. In this study, every 10-minute treatment 
delay resulted in 3.31 additional deaths in 100 PCI-treated CS patients 
without out-of-hospital cardiac arrest (136). Another recent study examined 
first medical contact to device time, and found that only one third of patients 
achieved the target of 90 minutes, and that first medical contact to balloon 
time > 90 minutes versus ≤ 90 minutes was independently associated with in-
hospital mortality (137). In addition, shorter symptom onset to balloon time 
(25,138) and shorter door to balloon time have been associated with better 
survival (138). Interestingly, in the SHOCK trial, the median time from shock 
to PCI was 5.3 hours, with  no association between shock onset to balloon time 
and mortality (121). 
2.3.6 Revascularization strategies 
Complete revascularization, in which the treatment goal is to address both 
culprit and haemodynamically significant non-culprit lesions during early 
revascularization, has historically been the preferred strategy in patients with 
ACS-related CS and was recommended in the CS guidelines (3,41). Indeed, in 
stable patients with STEMI, treatment of culprit- and non-culprit vessels at 
the time of primary PCI has proven feasible, safe, and has been  associated 
with better outcomes (139–141). In observational studies comparing 
multivessel- vs. culprit-vessel PCI strategy in CS patients, some studies have 
found multivessel PCI to be associated with better survival (142–144), 
whereas others have found no difference in outcome (121,145–148). A 
systematic meta-analysis showed higher short-term mortality in patients 
treated with multivessel PCI than with culprit lesion only PCI (149), while 
other meta-analyses  found no difference in outcome (150).  
The CULPRIT-SHOCK (Culprit Lesion Only PCI Versus Multivessel 
PCI in Cardiogenic Shock) trial randomized ACS-related CS patients with 
multivessel disease into two revascularization strategies: either PCI of the 
culprit lesion only, with the option of staged revascularization of non-culprit 
lesions, or immediate multivessel PCI (151). The strategy of PCI to the culprit 
lesion only was associated with lower risk of  the composite end-point of all-
cause mortality or of severe renal failure than was immediate multivessel PCI 
(151). A one year follow-up showed no mortality difference, but patients with 
PCI only of the culprit lesion needed more hospitalizations for heart failure 
and repeat revascularizations (152). Currently, ESC guidelines of myocardial 
revascularisation recommend culprit-lesion-only PCI as the default strategy 
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in patients with ACS-related CS. However, multivessel PCI may be considered 
in some patients, for instance, if difficulties arise in identifying the culprit 
lesion (87). 
Another treatment option for early revascularization in CS is 
emergency coronary artery bypass grafting (CABG). Currently, the rate of 
urgent CABG in patients with STEMI is reportedly around 4% to 10% 
(5,61,65,153) and even up to 29% in NSTEMI patients (135). Overall, data 
concerning CABG in CS patients are scarce. In a sub-analysis of the SHOCK 
trial, no differences in mortality appeared between CABG and PCI treatment, 
despite the fact that CABG was more often performed in patients with a high 
risk profile and advanced multivessel disease, whereas patients with fewer 
comorbidities and a lower extent of coronary artery disease prevailed in the 
PCI arm (154). In the SHOCK trial registry, mortality was higher in patients 
with PCI treatment than with CABG, especially in those patients with 
multivessel disease (122). In a prospective study conducted between 1995 and 
2004, mortality rates were numerically higher in the PCI group than in the 
CABG group (61). However, studies involving CABG and PCI treatment were 
not randomized, which means that selection bias should be considered; 
moreover, these studies were conducted back at the turn of the 21st century. 
Current ESC guidelines on revascularization suggest that CABG should be 
considered in CS patients with suitable anatomy, particularly if PCI is 
unfeasible (87). In addition, cardiologists and cardiac surgeons should make 
the decision about emergency CABG in collaboration, taking into account the 
patient’s medical history, coronary anatomy, procedural risks, potential 
treatment-related delays, and also patient preferences (3,44). 
2.3.7 Procedural characteristics of percutaneous coronary intervention 
Coronary artery perfusion beyond point of occlusion can be assessed with 
Thrombolysis in Myocardial Infarction (TIMI) grade flow classification (Table 
2) (155).  In CS, unsuccessful revascularization of the IRA (TIMI < 3 post-PCI) 
is associated with poor prognosis  (23–25,27–31,121,122). Currently, in ACS, 
the PCI procedure with balloon angioplasty and stent application is the 
recommended treatment method in ACS (87). In the SHOCK trial, only 34% 
of patients treated with PCI received stents, and coronary angiography was 
more often successful in stented than in non-stented patients (121). In 
addition, a study comparing outcomes between balloon angioplasty and stent 
placement showed a better outcome in CS patients with stenting (156).  
In STEMI overall, the benefit of drug-eluting stents in comparison with 
that of bare metal stents has been evident in trials (157,158). In CS, no 
randomized trials of drug-eluting stents versus bare metal stents have 
appeared, but one propensity-score-matched study found drug-eluting stents 
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to be associated with improved clinical outcomes (159), and the other found 
no difference between effects of the two type of stents (160). 
 
 
Table 2  TIMI grade flow descriptions (155). 
 
TIMI grade flow Description 
TIMI 0 - no perfusion no antegrade flow beyond the point of 
occlusion 
TIMI 1 - penetration without perfusion faint antegrade coronary flow beyond the 
occlusion with incomplete filling of the 
distal coronary bed 
TIMI 2 - partial perfusion delayed or sluggish antegrade flow with 
complete filling of the distal territory 
TIMI 3 - complete perfusion normal flow with complete filling of the 
distal territory 
 
 
Current guidelines for myocardial revascularization recommend, in 
general, radial access over femoral access (87), but in CS, hypotension and 
vasoconstriction may complicate transradial catheterization; moreover, the 
need for larger bore access for support devices may favour the transfemoral 
approach (161). No randomized trials between transradial and transfemoral 
access in CS patients have emerged, but observational studies (162,163) and 
a meta-analysis showed better outcomes with radial access than with femoral 
access (164). Expert recommendations for CS propose preferential use of the 
radial approach (3,44), and ultrasound guidance may serve to facilitate 
vascular access (165). 
In the setting of ACS-related CS, only sparse data are available on 
antithrombotic therapy. In general, dual antithrombotic therapy with aspirin 
and P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) is the 
recommendation in all patients treated with PCI (87). A secondary analysis of 
the ISAR-SHOCK (Efficacy Study of LV Assist Device to Treat Patients With 
Cardiogenic Shock) registry compared clopidogrel and prasugrel in ACS-
related CS, and found lower 30-day mortality in the prasugrel group (166). A 
sub analysis of the IABP-SHOCK II trial showed no difference in mortality 
between the clopidogrel and the ticagrelor or prasugrel groups, and no 
difference in bleeding complications (167).  
Impaired gastrointestinal absorption in the context of myocardial 
infarction may make oral administration of antithrombotic medications 
problematic  (166). Thus, intravenous antithrombotic medications such as 
glycoprotein IIb/IIIa inhibitors or the P2Y12 inhibitor cangrelor may be 
considered. Observational studies have shown improvement in survival and a 
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higher procedure success with abciximab (168–170) and in one observational 
study, cangrelor was associated with TIMI improvement better than with oral 
P2Y12 inhibitors, with a  similar risk for bleeding (171). Overall, expert 
guidelines recommend dual antiplatelet therapy in patients with PCI 
treatment in CS, and if oral administration is impossible or there is doubt 
about absorption, an intravenous glycoprotein IIb/IIIa inhibitor or P2Y12 
inhibitor can be considered (3). 
During PCI, an adjunctive anticoagulant is necessary. In choice of the 
anticoagulant, current expert recommendations are the same as for other 
types of ACS (3,44,87). If anticoagulation is required after PCI, the use of 
intravenous unfractionated heparin may be better than low-molecular weight 
heparin or fondaparinux, because of the high prevalence of acute kidney injury 
and acute liver injury (3). 
2.3.8 SYNTAX scores 
The SYNTAX score is an angiographic grading tool for the complexity of 
coronary artery disease calculated with a SYNTAX score algorithm, a 
computer program consisting of sequential and interactive self-guided 
questions (172). In this algorithm, each significant coronary artery lesion is 
evaluated separately, and the final SYNTAX score is the sum of the scores of 
each lesion. A lesion is defined as significant when it causes a ≥ 50% reduction 
in luminal diameter by visual assessment in vessels with minimal diameter of 
1.5 mm. The SYNTAX score algorithm consists of 12 main questions, which 
characterise each lesion explicitly (Table 3). Each coronary segment is 
classified according to its estimated contribution to relative blood supply for 
the left ventricle and receives a weighting factor. For example, the weighting 
factor for an LM lesion is 5 or 6 depending on coronary artery dominance, 
whereas for an RCA lesion it is 0 or 1 (172). 
Originally developed as a decision tool between PCI or CABG for 
patients with complex coronary artery disease (173), the SYNTAX has its 
baseline value calculated before any procedures to the coronary arteries. The 
prognostic value of baseline SYNTAX score was originally validated for long-
term mortality in stable coronary artery disease (173,174), and has now 
proven its prognostic effect in large PCI all-comers’ trials (175,176) as well as 
in STEMI (35–37,177) and in NSTEMI (178). One study evaluating baseline 
SYNTAX score in patients with STEMI-related CS found, for in-hospital 
mortality, 60% sensitivity and 59% specificity (179). In addition, a high 
baseline SYNTAX score has been associated with increased risk for CS (180), 
and the incidence of CS has been higher in patients with high baseline 
SYNTAX score (36,177). 
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Table 3 12 questions of the SYNTAX score algorithm 
 
1. Dominance 
2. Number of lesions 
3. Segments involved per lesion 
4. Total occlusions with subtotal occlusions 
 a. Number of segments 
 b. Age of total occlusions 
 c. Blunt stumps 
 d. Bridging collaterals 
 e. First segment beyond occlusion visible by antegrade or retrograde 
filling 
 f. Side branch involvement 
5. Trifurcation, number of segments diseased 
6. Bifurcation type and angulation 
7. Aorto-ostial lesion 
8. Severe tortuosity 
9. Lesion length > 20 mm 
10. Heavy calcification 
11. Thrombus 
12. Diffuse disease with number of segments 
 
Adapted from the SYNTAX score algorithm. Features in blue are lesion 
characteristics, specified separately for each lesion (172). 
 
Residual SYNTAX score is calculated after the PCI procedure (181) and 
can serve as an indicator of revascularization completeness. Residual SYNTAX 
score has been shown to have  prognostic value in all-comers’ PCI cohorts with 
complex coronary artery disease (182–189) as well as generally in ACS (181) 
and in STEMI (37–39). Complete revascularization is set at residual SYNTAX 
score 0 points, but in less than half the patients is complete revascularization   
achievable (39,181,185). This issue has led to the concept of reasonable 
incomplete revascularization, for which the residual SYNTAX score limit is set 
at 8 (39,182,185) or at 12 (188) points. In CS, residual SYNTAX scores await 
study. 
2.3.9 Complications of percutaneous coronary intervention 
Possible complications during the PCI procedure may include coronary artery 
dissection or perforation, side-branch occlusion, vascular complications, and 
arrhythmic complications such as ventricular fibrillation or tachycardia, or 
bradyarrhythmia due to sinus bradycardia or conduction block. In patients 
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with STEMI, incidence of any complication during LAD PCI has been 9% (33), 
with sustained ventricular arrhythmias witnessed in 4% of STEMI patients 
(190). One study reported procedural complications in patients with CS: the 
most common complication was coronary artery no-reflow or slow-flow in 
6.1% of the patients, followed by arrhythmia requiring direct cardioversion in 
4.4%, heart-block requiring temporary pacing in 3.9%, coronary dissection in 
2.3%, side-branch occlusion in 0.9%, and coronary perforation in 0.4% (31). 
 
2.4 Electrocardiography in cardiogenic shock 
2.4.1 ST-segment elevation and depression 
The ECG examines cardiac activity through electrical potentials measured 
from the surface of the body. In many pathologic circumstances, electrical 
potentials within the myocardium are altered, being reflected in the standard 
12-lead ECG. ST-segment changes in CS have only been studied in the context 
of ACS, but in addition to myocardial ischaemia, ST-segment deviations are 
observable in other cardiac conditions such as acute pericarditis, myocarditis, 
LV hypertrophy, Brugada syndrome, or stress-induced cardiomyopathy (7,8). 
In an acute setting, reciprocal changes may help to differentiate STEMI from 
pericarditis or early repolarization changes (48,191). Diagnostic criteria for 
ST-segment deviations in this study are described in Table 4. 
 
 
Table 4 Definitions of ST-segment deviations. 
 
 Definition 
STE 
ST-segment elevation  
ST-segment elevation at the J point in two contiguous leads 
with cut-off points: ≥ 0.1 mV in all leads other than leads V2–
V3, in which these cut-off points apply: ≥ 0.2 mV in men ≥ 40 
years, ≥ 0.25 mV in men < 40 years or ≥ 0.15 mV in women 
STDEP 
ST-segment depression 
Horizontal or down-sloping ST-segment depression ≥ 0.05 
mV in two contiguous leads 
NSTED 
No ST-segment deviation 
or ST-segment impossible 
to analyse 
ECGs with confounding ST-segment pattern: Left bundle 
branch bloc (LBBB), ventricular paced rhythm, ECGs with 
other changes (Q waves, T inversion without ST deviation, or 
a normal ECG. 
 
Adapted from the Third Universal Definition of Myocardial Infarction (192). 
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Pathogenesis of STE has previously been examined closely. Acute ischaemia 
due to compromised blood supply to the myocardium alters the electrical 
properties of the myocardium, thus leading to repolarization abnormalities. 
In general, STE results from electrical changes associated with transmural 
ischaemia (Figure 3) (193). After coronary artery occlusion, the ischaemic 
myocardial cells consume all available oxygen within minutes. When oxygen 
is no longer available, oxidative phosphorylation comes to a complete halt. In 
the ischaemic heart, hydrolysis of adenosine triphosphate results in large 
amounts of phosphate, which pours out into the intracellular space. In order 
to maintain electrical neutrality, phosphate anions are accompanied by 
potassium, the major intracellular cation. This causes a large potassium efflux, 
which results in depolarization of the ischaemic myocardial cells (194). The 
depolarization of ischaemic myocardial cells causes an electrical gradient 
between the resting potentials of ischaemic and viable myocardium that allow 
the current to flow between the normally perfused and ischaemic regions of 
the heart. These injury currents are visible on the surface ECG as STE 
(193,195). In addition to the injury currents, a second theory explains STE as 
a difference in plateau potentials of the epicardium and endocardium, because 
ischaemia causes depression of the action potential plateau in the epicardium 
but not in the endocardium, resulting in a transmural voltage gradient (196).  
 
 
Figure 3 The development of ST-segment elevation. The mean spatial ST-
vector is directed toward the area of predominant epicardial injury. 
Reproduced with the permission of Wiley (197). 
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Especially in STEMI, ECG patterns are well characterised. The ECG changes 
begin rapidly after total coronary artery occlusion, and without therapeutic 
intervention, these changes progress typically (198). The first findings are 
hyperacute T waves, following STE, abnormal Q waves, T-wave inversion, and 
finally, normalization of the ST segment (191,199,200). Because acute 
myocardial ischaemia results in dynamic changes in ECG pattern, serial ECG 
acquisition can provide critical information (48). The localisation of STE often 
reveals the culprit artery, since anteroseptal STE is associated with LAD 
occlusion, and inferior or lateral STE with LCX or RCA occlusion (201,202). 
In addition, the localisation of STE is associated with prognosis of ACS, with 
patients having anterior STE showing worse outcome than to those with 
inferior or lateral STE (203,204).  
The pathophysiology of STDEP is more elusive. Traditionally, the view 
is that STDEP results from subendocardial ischaemia. In this theory, a layer 
of perfused myocardium separates the partially depolarized endocardium 
from the epicardial surface of the heart, which is reflected as STDEP (Figure 
4) (205). STDEP is common in demand ischaemia, because the workload of 
the subendocardial myocytes of the left ventricle is greater than that of the 
myocytes of the epicardium, due to the unique anatomy of the left ventricle. 
Consequently, energy demands are highest in the endocardium, making the 
endocardium more prone to energy starvation than is the epicardium (197). 
Overall, STDEP and subendocardial ischaemia are not well defined in the 
current literature, because reproducing subendocardial ischaemia in animal 
models has proven difficult (206). In general, STDEP does not localize cardiac 
ischaemia (205).  However, global ischaemia pattern, with STDEP > 1 mm in 
six leads, associated with STE in leads aVR or lead V1, is suggestive of 
widespread ischaemia resulting from multivessel disease or LM disease 
(48,207), and it has been associated with worse ACS outcome (208). This 
pattern has not been studied in CS patients, however. 
In general, studies reporting ECG changes in CS are scarce. In the 
SHOCK trial, patients often had extremely abnormal ECG characteristics such 
as persistent STE, widespread STDEP, and a high incidence of conduction 
abnormalities (20). An association appeared between the total sum of STDEP 
of all leads and 1-year mortality in those randomized to initial medical 
stabilization, but not in those randomized to emergency revascularization 
(20). One study reported that a higher total ST sum of ST deviation was 
associated with CS development in ACS patients (209). 
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Figure 4 The development of ST-segment depression. The mean spatial ST-
vector is directed away from subendocardial injury, causing STDEP. 
Reproduced with the permission of Wiley (197). 
 
ST-segment patterns have only been addressed in studies investigating 
STEMI and NSTEMI, but not in patients with other CS aetiologies. CS 
incidence is higher among STEMI patients than among those with NSTEMI 
(6% to 12% vs. 2% to 4%) (1,62,65,135). Patients with NSTEMI are older, 
more often female, and have more comorbidities than do patients with STEMI 
(62,210,211). Short-term mortality rates in STEMI-related CS have been 
reported at 33% to 45% (1,62,212) in comparison to 34% to 41% in NSTEMI 
(1,62,135). Three studies reported NSTEMI patients to have higher mortality 
than STEMI in CS (60,62,210), while two studies found no mortality 
difference (11,211). A large registry study from the USA reported that in CS-
related STEMI, mortality rates were highest when CS developed during the 
first 24 hours of hospitalisation, in comparison to CS at admission or after 24 
hours of hospitalisation, while in NSTEMI, those patients with CS at 
admission had the highest short-term mortality rates (10).  
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2.4.2 Ventricular conduction disturbances 
Under normal conditions, the action potential generated by the sinoatrial 
node spreads through the atria to the atrioventricular (AV) node, from where 
it continues to the ventricles through the bundle of His, bundle branches, and 
fascicles, and finally to the Purkinje fibres, which produce rapid and 
synchronous depolarization and contraction of ventricular cardiomyocytes. 
Left bundle branch block (LBBB) results from a conduction disturbance in the 
predivisional segment of the left bundle branch, or in both left anterior and 
posterior fascicles. This causes alteration of the normal sequence of activation 
in the myocardium, with the ECG showing a characteristic LBBB appearance. 
If the disturbance is only in the anterior or posterior fascicle, it leads to left 
anterior hemiblock (LAHB) or left posterior hemiblock (LPHB) (213). 
Correspondingly, right bundle branch block (RBBB) results from conduction 
disturbance in the right bundle branch. Unspecified intraventricular 
conduction delay (IVCD) refers to a situation in which QRS duration is 
prolonged, but the diagnostic definitions for any conduction block is 
unfulfilled. For definitions of each conduction disturbance see Table 5. 
  
Table 5 Definitions used for of ventricular conduction blocks in this study. 
 
Block type Definition 
LBBB QRS duration ≥ 120 ms  
Tall R, broad or notched R waves in the lateral leads (I, V5-6) 
 Deep S waves in the right precordial leads (V1-3)  
Absence of septal Q waves in the lateral leads (I, V5-6) 
RBBB QRS duration ≥ 120 ms  
Wide or notched R wave in leads V1 or V2 
Slurred S wave of greater duration than R wave in leads I and V6 
LAHB Left axis deviation (-30° to -90°)  
qR pattern (small q, tall R) in the lateral limb leads I and aVL  
rS pattern (small r, deep S) in the inferior leads II, III, and aVF 
QRS width < 120 ms (in the absence of RBBB) 
LPHB Right axis deviation (90°-180°)  
rS pattern in leads I and aVL  
qR pattern in leads III and aVF  
QRS width < 120 ms (in the absence of RBBB) 
IVCD QRS ≥ 110 ms without bundle branch blocks and hemiblocks 
 
Adapted from AHA/ACCF/HRS recommendations for the standardization and 
interpretation of the electrocardiogram: part III: intraventricular conduction 
disturbances (214). 
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In the general population, the prevalence of different ventricular 
conduction blocks is low, around 1% (215,216). Ventricular conduction blocks 
may be associated with various cardiac conditions such as ischaemic heart 
disease, cardiomyopathies, hypertension, or congenital heart disease 
(217,218). In CS, ischaemia (219), or overstretching of the conduction fibres 
due to ventricular wall stress (220,221), may damage the conduction network 
within the ventricles, resulting in slow impulse conduction through the 
cardiomyocytes, seen in ECG as intraventricular conduction disturbances. The 
term ‘intraventricular conduction disturbance’ comprises all abnormalities in 
intraventricular conduction that result in changes in the shape or duration, or 
both, of the QRS complex. 
Ventricular conduction disturbances induced by ischaemia are often 
visible in the form of conduction blocks (222). Since the myocardium is less 
resistant to ischaemia than is the conduction system, occurrence of a bundle 
branch block may relate to extensive and on-going myocardial infarction 
(17,223). Appearance of a new RBBB may be explained by occlusion in the 
proximal section of the LAD before the septal branches, because the course of 
the right bundle branch goes through the anterior septum (224,225). More 
extensive injury is required to cause LBBB, as the left bundle branch is 
supplied usually by two of the three main coronary arteries: the septal 
branches of the LAD and the AV nodal branch, which is a distal branch of the 
RCA or less frequently a branch of the LCX (225). The structure of the left 
anterior fascicle is thin and long and is thus susceptible to ischaemia. It is 
supplied by septal branches of the LAD (226). In contrast, the left posterior 
fascicle is short and thick and better protected from ischaemia, as it has a 
double blood supply from the LAD and the posterior descending branch, 
which is usually a distal branch of the RCA (226,227) (Figure 5). 
Ischaemia can also cause QRS complex prolongation, seen as IVCD. 
This kind of conduction disturbance is explained by injured myocardium, in 
which the areas of slowed ventricular activation and electrically inactive tissue 
cause increased duration of depolarization, resulting in QRS prolongation 
(222). In studies addressing slowed ventricular activation, the prolongation of 
depolarization is considered to be characteristic of a peri-ischaemic block 
(17,18). Due to the reversible mechanism, ischaemia-related QRS 
prolongation is often transient (17,18). In addition to conduction blocks and 
QRS prolongation, changes in the amplitude of QRS are common, i.e. the 
increase in amplitude of R waves and disappearance of S waves, which are 
explained by prolongation of electrical conduction in the Purkinje fibres in the 
ischaemic region (9). These kinds of changes may lead to a shift in the 
electrical axis, resulting in a hemiblock configuration (9,222,228). Overall, 
changes in the QRS pattern and duration are usually complimentary to ST-
segment deviation and may reflect more severe ischaemia and progression of 
irreversible myocardial necrosis (9,229). 
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Figure 5 Arterial supply of the conduction system. AV = atrioventricular, LAD = 
left anterior descending artery, LCX = left circumflex artery, RCA = 
right coronary artery. Reproduced with permission of the illustrator 
(230). 
 
In ACS patients with ventricular conduction disturbances, CS incidence 
is up to 19% (10,12–14) and higher than that reported in STEMI (1,62,65). 
One study found that, in patients with STEMI, RBBB was an independent 
predictor of CS development (209). RBBB and LBBB were more common in 
patients with anterior myocardial infarction than with other infarct locations 
(12,204), and RBBB was associated with LAD as the culprit artery and LBBB 
with RCA as the culprit artery (12). Three studies have reported the prevalence 
of ventricular conduction disturbances in CS patients, in whom RBBB was 
present in 13% to 20%, and LBBB in  2% to 10% (11,20,209). A small study of 
CS patients with LM as the culprit artery reported a prevalence of RBBB as 
high as 48% (21). Reversion of ventricular conduction blocks in acute 
ischaemia is common, and new-onset blocks are more likely to revert back to 
normal (231,232). 
In ACS, ventricular conduction disturbances have been associated with 
worse outcome (11,12,14–16). Some studies have found higher mortality in 
general with ventricular conduction blocks, but no difference in survival 
between LBBB and RBBB (14), especially in long-term follow-up (15). In 
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GUSTO I trial patients, RBBB + LAHB showed the strongest association with 
mortality, followed by isolated RBBB. In addition, post-thrombolytic 
reversion of the bundle branch block was associated with better survival in 30 
day follow-up (12). Another study had similar results, since it showed that 
RBBB was associated with poor outcome, and higher mortality was especially 
associated with new-onset RBBB in comparison with old RBBB, persistent 
RBBB in comparison with reversible RBBB, and bifascicular RBBB in 
comparison with isolated RBBB (16). Another study also reported that new-
onset BBB was associated with worse outcome in comparison with old BBB 
(14). A more recent study reported that in-hospital mortality was highest 
among patients presenting with new or presumably new RBBB, followed by 
new or presumably new LBBB, old LBBB, and old RBBB (13).  
Few studies have examined ventricular conduction disturbances in CS. 
In the SHOCK trial, prolonged QRS was associated with increased 1-year 
mortality in patients randomized to initial medical stabilization, but not in 
those randomized to emergency revascularization (20). In two studies of ACS-
related CS, RBBB was associated with poor short- and long-term prognosis 
(11,21). 
2.4.3 Heart rate and arrhythmias 
In ACS patients, higher heart rate at admission has been associated with 
higher CS incidence (153,209) and with worse outcome (81,233). Previously, 
higher heart rate was associated with increased one-year mortality in the 
SHOCK trial patients (20) as well as in STEMI-related CS patients (234). An 
elevated heart rate slows the decrease in cardiac output, but it also raises 
myocardial oxygen consumption. In addition, myocardial perfusion time 
decreases (235). Heart rate elevation may be iatrogenic, since the most 
commonly chosen inotrope dobutamine causes tachycardia, which may 
contribute to haemodynamic compromise and may predispose to arrhythmias 
(236). As β-blockers are contraindicated in unstable patients (3,109), selective 
heart rate reduction may be better tolerated in patients with CS. Ivabradine is 
the only selective heart-rate-lowering agent that acts by inhibition of the I(f)-
channel in the sinus node, thus having no effect on haemodynamics or on 
myocardial contractility (237). In two small studies in CS patients, ivabradine 
was well tolerated and was also associated with short-term favourable 
outcomes (238,239), but use of ivabradine in patients with cardiogenic shock 
is experimental, and by far only recommended in stable heart failure (41). 
In CS patients, the overall incidence of atrial fibrillation is 10% to 30%. 
In ACS, atrial fibrillation has been associated with worse outcome (240,241). 
In CS, several mechanisms expose patients to atrial fibrillation, notably 
increase in capillary wedge pressure and in left atrial pressure (242). One 
hypothesis is that, in CS, atrial fibrillation causes haemodynamic instability 
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resulting from loss of atrial contraction and of AV synchrony, from rapid 
ventricular rates, and from irregular RR interval; atrial fibrillation may thus 
lead to worsening symptoms and to worse clinical outcomes. (242). However, 
an IAPB-SHOCK II trial substudy found no difference in mortality between 
patients presenting with or without atrial fibrillation in 30-day and 1-year 
follow-up (243).  
In ACS-related CS, ventricular tachycardias are common (242). 
Sustained ventricular tachycardias have been reported in 17% to 21% and 
ventricular fibrillation in 20% to 29% (153,234,244). Especially in CS, 
sustained ventricular tachycardias are prone to causing haemodynamic 
collapse, which is why immediate direct current cardioversion is 
recommended (242). Antiarrhythmic therapy and electrolyte balance 
correction should also be considered (245), taking into account the 
hypotensive likelihood of intravenous administration of amiodarone (246). If 
ventricular tachycardia is recurrent, catheter ablation may be indicated as a 
salvage procedure (242,247).   
2.4.4 Atrioventricular conduction disturbances 
The incidence of high-grade AV block in ACS has declined due to improved 
therapeutic interventions (248). In ACS-related CS, high-grade AV block and 
asystole develop in about 10% to 35% of all patients (30,153,209), with 
inferior infarctions resulting from proximal RCA occlusion being the main risk 
factor (249). In ACS-related CS, bradyarrhythmias are induced by either 
necrosis of the conduction system or by autonomic imbalance with vagal 
hyperactivity (242). In ACS patients, high-grade AV block is associated with 
higher mortality (248–250), but its significance as a prognostic marker in CS 
patients is unknown. For patients with severe life-threatening 
bradyarrhythmias, emergency temporary transvenous pacing is necessary, 
especially if the arrhythmias do not resolve within a few minutes after 
reperfusion (109,242,251).      
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3 AIMS OF THIS STUDY 
This study investigated electrocardiographic and angiographic features in 
patients with CS. First, we studied the prevalence of various parameters in 
standard 12-lead ECG and examined their effect on survival. Secondly, we 
studied angiographic features, including the extent of coronary artery disease, 
procedural success, and baseline and residual SYNTAX scores, and assessed 
their prognostic significance in CS.  
 
In more detail, the aims were: 
 
1. To describe the prevalence of different ST-segment deviations and their 
association with CS aetiology, clinical findings, and 90-day mortality in 
CS patients with various aetiologies. (I) 
 
2. To assess the prevalence, temporal evolution, and the impact on 
survival of ventricular conduction blocks in patients with ACS-related 
CS. (II) 
 
3. To describe the baseline and residual SYNTAX score values in STEMI-
related CS patients and to evaluate their added prognostic value over 
baseline covariates and clinical risk scores. (III) 
 
4. To analyse the angiographic features, the effect of procedural timing, 
and the success of percutaneous coronary intervention in patients with 
ACS-related CS. (IV) 
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4 SUBJECTS AND METHODS 
4.1 The CardShock Study  
This is an observational study based primarily on the CardShock study, a 
prospective, observational, multinational study of CS. The CardShock study 
was coordinated by the Heart Failure Study Group of Helsinki University 
Hospital and was conducted in eight countries (Czech Republique, Denmark, 
Finland, Greece, Italy, Poland, Portugal, and Spain) and in nine centres across 
Europe. The recruitment period was from October 2010 to December 2012.  
The CardShock study enrolled consecutive patients aged over 18 years 
within six hours after detection of CS. The criteria for shock were SBP < 90 
mmHg for 30 minutes despite accurate fluid therapy, or a need for vasoactive 
therapy and ≥ 1 signs of inadequate organ perfusion: confusion or altered 
mental status, cool extremities, oliguria < 0.5 ml/kg/h for the previous 6 h, or 
blood lactate > 2 mmol/l. Patients were excluded for ongoing 
haemodynamically significant arrhythmia and shock after cardiac or non-
cardiac surgery.  
Patients’ demographic characteristic and comprehensive medical 
history were collected, with clinical signs and laboratory measurements 
registered at baseline and every 6 to 24 hours. Creatinine, C-reactive protein 
(CRP), high-sensitive troponin T (hs-TnT, Elecsys, Roche Diagnostics, Basel, 
Switzerland), and N-terminal pro-natriuretic peptide (NT-proBNP, Elecsys, 
Roche Diagnostics) were measured at a central laboratory (ISLAB, Kuopio, 
Finland). Arterial blood lactate and pH were analysed locally. Estimated 
glomerular filtration rate (eGFR) was calculated from creatinine values by the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. 
ECGs were recorded at baseline and at day 3. The echocardiogram was 
performed per protocol at study entry. Patients were treated according to local 
practise and treatments, and procedures were registered and detailed 
information from coronary angiography was collected. 
The CardShock study was accepted by local ethics committees at the 
participating centres except for Denmark, Copenhagen. Approval from the 
Danish Ethics committee was unnecessary, as the Danish law does not require 
ethical approval if the study utilizes information from existing registries, but 
approval of the study came from the Danish Protection Agency. The 
CardShock study was conducted in accordance with the Declaration of 
Helsinki. All patients or their next of kin provided informed consent. The 
primary endpoint was 90-day mortality in Studies I, III, and IV and was one-
year mortality in Study III; three patients were lost to follow-up. 
The descriptions of the study population and predictors of in-hospital 
mortality were published previously (85). Briefly, the main aetiology of CS was 
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ACS (81%). Other causes of CS were exacerbation of chronic heart failure, 
valvular dysfunction, stress-induced cardiomyopathy, and myocarditis. In 
comparison of patients with ACS and non-ACS aetiology, ACS patients were 
older (68 ± 11 years vs. 62 ± 15 years) and more often were men (88% vs. 
57%).  In-hospital mortality was 40% in ACS and 24% in non-ACS patients. A 
risk prediction model called the CardShock risk score we developed from the 
clinical and biological parameters incorporating seven variables with a 
maximum of nine points (Table 6). The CardShock risk score performed well 
in prediction of in-hospital mortality in the CardShock cohort with an area 
under the curve (AUC) of 0.85 (95% CI 0.80 to 0.90) (85). 
 
 
Table 6 The CardShock risk score (85) 
 
Variables Score 
Age >75 years 1 
Confusion at presentation 1 
Previous myocardial infarction 
or CABG 
1 
ACS aetiology 1 
LVEF <40%  1 
Blood lactate 
 
<2 mmol/L  0 
2-4 mmol/L 1 
>4 mmol/L  2 
eGFRCKD-EPI 
 
>60 mL/min/1.73m2 0 
30-60 mL/min/1.73m2 1 
<30 mL/min/1.73m2 2 
Maximum 9 
 
Abbreviations: ACS = acute coronary syndrome, CABG = coronary artery bypass graft 
surgery, eGFRCKD-EPI = estimated glomerular filtration rate by the Chronic Kidney 
Disease Epidemiology Collaboration formula, LVEF = left ventricular ejection fraction. 
Reproduced with the permission of Wiley. 
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4.2 Study population and study outlines 
4.2.1 Study I 
Study I included 196 CardShock patients with a baseline ECG available. A 
subgroup analysis involved patients with ACS-related CS. Topics of the study 
were the prevalence of ST-segment deviations in baseline ECG and their 
association with CS aetiology and mortality. 
The baseline ECG analysis utilised a custom‐made non‐commercial 
software engineered for ECG analysis at the University of Helsinki. The 
examiner defined electronically for the analysis program the baseline of the 
ECG at the level of the PQ interval and all key points in each ECG: the start 
and end points of the P wave, each component of the QRS‐complex 
individually, the J point and the ST‐segment at 0.04 and 0.08 s after the J 
point, and the start, peak, and end points of the T‐wave. The software 
calculated time intervals and voltage differences between the specified points 
and the ECG baseline. 
ST-segment deviations were defined according to the third universal 
definition of myocardial infarction (192). ECGs with LBBB or ventricular 
paced rhythm were excluded from ST-segment analysis. Patients were divided 
into three groups according to their ST-segment pattern: ST-segment 
elevation (STE), ST-segment depression (STDEP), and no ST-segment 
deviation or ST-segment impossible to analyse (NSTD). Those patients with 
both STE and STDEP were included in the STE group. STE localisation was 
assessed in patients with STE. 
4.2.2 Study II 
Study II included 199 patients with ACS-related CS from two different 
cohorts. A larger cohort of 155 were CardShock patients with ACS aetiology 
and baseline ECG available. A second cohort of 44 included patients from 
another prospective observational study of ACS-related CS conducted at the 
Brno University Hospital in the Czech Republic (58). The enrolment period 
for the second cohort was between January 2006 and June 2011.  The 
inclusion criteria for the Brno University CS study were similar those of the 
CardShock study, and the exclusion criteria were ongoing resuscitation since 
the time of admission without return of spontaneous circulation, non-
confirmation of ACS as the cause of CS, non-acquisition of the study consent 
form, malignancy, and inflammatory disease or connective tissue disease. 
Originally, the Brno University CS study included 80 patients, but only those 
44 with baseline ECG available we included in Study II. 
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The baseline and day-3 ECGs were analysed by three independent 
researchers. QRS duration was analysed with a custom‐made non‐commercial 
software engineered for ECG analysis at the University of Helsinki as 
described in Study I. QRS configuration and rhythm we analysed visually. 
LBBB and RBBB we defined by standard criteria (252). LAHB we defined as 
QRS axis between -45 and -90°, qR/R in leads I and aVL, rS in leads II, III, 
and aVF, and QRS <120 ms if without concomitant RBBB. LPHB was defined 
as QRS axis > 90°, qR complex in lead III and rS complex in lead I, and QRS 
< 120 ms, if without concomitant RBBB. IVCD was identified as QRS duration 
≥ 110 ms not fulfiling the criteria of either bundle branch block or hemiblock 
(253,254). Temporal evolution of conduction pattern was assessed from 
baseline to day 3. Investigation of the pre-existence of the block required a 
retrospective search of the previous ECGs of those patients with a ventricular 
conduction block in the baseline ECG from the three largest study centres 
(Helsinki, Brno, Barcelona). 
4.2.3. Study III 
Study III included CardShock patients from the two largest CardShock centres 
(Helsinki and Barcelona). The 61 STEMI patients included those treated with 
primary or rescue PCI and those with angiograms available. STEMI was 
defined according to the third universal definition of myocardial infarction 
(192). SYNTAX scores were calculated from the angiograms by means of the 
SYNTAX score algorithm (172) by two investigators blinded to patient data. 
The SYNTAX scores were calculated at three points. Baseline SYNTAX 
score 1 was measured from the initial diagnostic angiogram, and baseline 
SYNTAX score 2 was measured after wiring or thrombectomy. If TIMI flow 
did not improve, or the anatomy of the IRA could not be assessed, baseline 
SYNTAX score 2 was the same as Baseline SYNTAX score 1. The residual 
SYNTAX score was calculated after completion of primary PCI. If staged 
angiograms were performed during the hospital stay, residual SYNTAX score 
was measured after all PCI procedures. 
4.2.4 Study IV 
Study IV included 158 CardShock patients with ACS-related CS with 
angiographic data available. The treating physician analysed the angiographic 
images. The characteristics of coronary artery disease, including the extent of 
coronary artery disease and the culprit artery, underwent analysis. Procedural 
characteristics examined included type and number of stents, symptom-to-
balloon time, success of revascularization, and complications during the PCI 
procedure. 
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 Table 7 summarizes specific inclusion criteria and the number of 
included and excluded patients in each study. 
 
Table 7 Number of included and excluded patients in each Study 
  
Study I Study II Study III Study IV 
Inclusion 
criteria 
▪ Any CS cause 
▪ Baseline ECG    
available 
▪ CS cause: ACS  
▪ Baseline ECG 
available 
▪ CS cause: STEMI  
▪ patients from Helsinki 
or Barcelona 
▪ Primary or rescue PCI 
▪ No previous CABG 
▪ Angiographic data 
available 
▪ CS cause: ACS 
▪ Angiographic 
data available 
Card Shock 
patients 
included, n 
196 155  61 158 
Excluded, 
total n 
23 64 158 61 
Cause of 
exclusion, n 
No baseline 
ECG, 21 
Other CS 
aetiology, 42 
Patients from a centre 
other than Helsinki or 
Barcelona, 95 
CS aetiology 
other than ACS, 
42  
Idioventricular 
rhythm, 2 
No baseline 
ECG, 16 
CS aetiology other than 
STEMI, 42 
No angiography 
performed, 10   
Only ventricular 
paced 
complexes or 
idioventricular 
rhythm, 6 
No primary or rescue 
PCI, 14 
No data on 
angiography, 6 
   
Previous CABG, 3 Lost to follow-
up, 3    
Angiography 
unavailable, 4 
 
Brno patients 
included 
 
44 
  
Excluded  40   
Cause of 
exclusion 
 No baseline 
ECG, 40 
  
 
Abbreviations: ACS = acute coronary syndrome, CABG = coronary artery bypass graft 
surgery, ECG = electrocardiogram, CS = cardiogenic shock, PCI = percutaneous 
coronary intervention, STEMI = ST-segment elevation myocardial infarction 
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4.3 Statistical Methods 
Continuous results are presented as means and standard deviations (SD) or 
medians and interquartile ranges (IQR) and categorical variables as counts 
(percentages). Continuous variables were analysed with a T-test, Mann–
Whitney U test, or Kruskal–Wallis test, as appropriate. Categorical variables 
were analysed with Chi-square test or Fisher’s exact test. 
The Kaplan–Meier method served to generate survival curves, and log‐
rank test to assess differences in survival. Univariable and multivariable Cox 
regression analyses for the risk of 90-day death were conducted. Univariable 
p‐values were calculated for the control variables, and significant associates 
were included in the multivariable analysis. The final Cox regression models 
were formed applying stepwise selection. 
In Study III, the predictive power of SYNTAX scores was assessed by 
use of receiver operating characteristic (ROC) curves. The interobserver 
variability (tertial partitioning) for the SS examiners was calculated in 48 
independently analysed angiograms with Cohen’s Kappa statistics. 
A two‐tailed p‐value of < 0.05 was considered statistically significant. 
The confidence intervals (CIs) were calculated at the 95% significance level. 
In Studies I-III, the statistical analyses were performed using IBM SPSS 
Statistics for Windows, version 21 or 24 (IBM Corp., Armonk, NY, USA). In 
Study IV, the analyses were performed using R statistical software version 
3.4.3 or above (The “R” Foundation for Statistical Computing, Vienna, 
Austria). 
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5 RESULTS 
5.1 ST-segment deviations in cardiogenic shock (I) 
5.1.1 Prevalence and association with ACS aetiology 
Study I included 196 CardShock patients with baseline ECG available. Mean 
age was 66 ± 12 years old, and 74% men.  
ST-segment deviations were observable in 157 patients (80%). More 
than half the patients had STE and 29% had STDEP. The remaining 20% had 
no ST-segment deviation, or the ST-segments were impossible to analyse 
(NSTD) (Figure 6A). No differences in age or gender emerged across study 
groups. STE patients had fewer comorbidities than in the other two groups, 
but they were more often smokers (Table 8). 
 
 
 
Figure 6 A) Prevalence of ST-segment deviations. B) ACS aetiology in patients 
with different baseline ECG ST-segment patterns. Abbreviations:  
NSTD = No ST-segment deviation or ST-segment impossible to 
analyse, STE = ST-segment elevation, STDEP = ST-segment depression. 
Reproduced with publishers permission from Study I (255). 
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Table 8 Baseline characteristics of Study I patients 
 
    STE 
101 
STDEP 
56 
NSTD 
39 
p 
Age, years 66 ± 12 69 ± 13 65 ± 12 0.16 
Male gender (%) 76 (75) 38 (68) 31 (79) 0.41 
Coronary artery disease (%) 28 (28) 22 (39) 18 (46) 0.04 
Previous myocardial 
infarction (%) 
24 (24) 14 (25) 10 (26) 0.97 
Previous CABG (%) 5 (5) 4 (7) 3 (8) 0.76 
Chronic heart failure (%) 10 (10) 14 (25) 8 (21) 0.04 
Diabetes (%) 30 (30) 15 (27) 12 (31) 0.90 
Hypertension (%) 61 (60) 33 (59) 23 (59) 0.98 
Hypercholesterolemia (%) 49 (49) 25 (45) 18 (46) 0.89 
Smoking (%) 48 (48) 18 (32) 13 (33) 0.03 
Atrial fibrillation (%) 8 (8) 11 (20) 9 (23) 0.03 
SBP, mmHg  78 ± 16 76 ± 12 80 ± 12 0.29 
LVEF, % 35 ± 14 32 ± 15 32 ± 14 0.35 
eGFR, ml/min/1.73m2 60 (42-86) 62 (36-86) 67 (43-95) 0.71 
Lactate, mmol/l 3 (2-6) 3 (1-5) 3 (2-6) 0.11 
Hs-TnT, ng/l  3803 (1366-
8849) 
1132 (255-
2761) 
407 (115-
2096) 
0.02 
NT-proBNP, ng/L 1611 (266-
7649) 
6020 (731-
15754) 
3160 (1501-
7619) 
0.15 
 
Data presented as counts (percentages), means ± SD or medians (IQR). 
Abbreviations: ACS = acute coronary syndrome, CABG = coronary artery bypass 
grafting, eGFR= estimated glomerular filtration rate, hs-TnT = high-sensitive troponin 
T, LVEF = left ventricular ejection fraction, NSTD = No ST-segment deviation or ST-
segment impossible to analyse, NT-proBNP = N-terminal pro-natriuretic peptide, SBP 
= systolic blood pressure, STE = ST-segment elevation, STDEP = ST-segment 
depression 
 
The most common CS aetiology was ACS in 159 (81%) patients. ACS aetiology 
was more common in the STE group than the STDEP or the NSTD groups 
(93% vs. 73% and 62%; both p < 0.01, Figure 6B). Other aetiologies of CS are 
described in Table 9. 
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Table 9 Aetiologies of cardiogenic shock 
 
 STE 
101 
STDEP 
56 
NSTD 
39 
ACS (%) 94 (93) 41 (73) 24 (62) 
Exacerbation of chronic heart failure (%) 4 (4.0) 6 (11) 11 (28) 
Valvular stenosis (%) 1 (1.0) 4 (7.1) 0 (0) 
Valvular regurgitation (%) 1 (1.0) 2 (3.6) 0 (0) 
Stress-induced cardiomyopathy (%) 0 (0) 1 (1.8) 3 (7.7) 
Myocarditis (%) 1 (1.0) 2 (3.6) 1 (2.6) 
 
Data presented as counts (percentages). Abbreviations: ACS = acute coronary 
syndrome, NSTD = No ST-segment deviation or ST-segment impossible to analyse, 
STE = ST-segment elevation, STDEP = ST-segment depression 
5.1.2 Association of ST-segment deviations and mortality 
During 90-day follow-up, 80 (41%) patients died. Mortality rates were similar 
between patients with different ST-segment patterns: in STE 47 (47%), in 
STDEP 20 (36%) and in NSTD 13 (33%) (p = 0.15, Figure 7A). Among the STE 
group, patients with anterior STE had a higher 90-day mortality rate than did 
patients with inferior STE (29 (56%) vs. 10 (28%); p = 0.01, Figure 7B). 
In multivariable mortality analysis, STE was associated with worse 
outcome (HR 1.74, 95% CI 1.07 to 2.84; p = 0.03) when adjusted with 
significant covariates (age, history of coronary artery disease, SBP, lactate, and 
LVEF). Neither STDEP nor NSTD was associated with outcome in 
multivariable mortality analysis (Table 10A).  
Patients with ACS tended to have higher mortality than did patients 
with other CS aetiologies (69 (43%) vs. 11 (30%); p = 0.09).  
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Figure 7 Kaplan–Meier 90-day survival curves (A) in all the study patients with 
the ST-segment patterns studied, (B) in STE patients with different STE 
locations, (C) in the ACS subgroup with the ST-segment patterns 
studied. Abbreviations: ACS = acute coronary syndrome, NSTD = No 
ST-segment deviation or ST-segment impossible to analyse, STE = ST-
segment elevation, STDEP = ST-segment depression. Reproduced with 
publishers permission from Study I (255).  
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Table 10  Multivariable 90-day mortality analyses 
 
 A: All patients 
HR (95% CI) 
 p B: ACS subgroup 
HR (95% CI) 
p 
STE 1.74 (1.07 to 2.84) 0.03 1.55 (0.88 to 2.73) 0.13 
STDEP 0.58 (0.33 to 1.02) 0.06 0.69 (0.37 to 1.29) 0.24 
NSTD 0.81 (0.43 to 1.53) 0.52 0.79 (0.37 to 1.73) 0.56 
 
Multivariable model adjusted for age, history of coronary artery disease, systolic 
blood pressure, lactate and left ventricular ejection fraction. Abbreviations: NSTD = 
No ST-segment deviation or ST-segment impossible to analyse, STE = ST-segment 
elevation, STDEP = ST-segment depression 
5.1.3 ACS subgroup analysis 
The ACS subgroup comprised of 159 patients. Among these patients, almost 
everyone underwent coronary angiography (94%) and PCI was performed in 
the vast majority (STE 92%, STDEP 87% and NSTD 86%; p = 0.48). STE 
patients less often had three‐vessel disease than did the STDEP patients (24% 
vs. 42%; p = 0.04) (Table 11). 
In the ACS subgroup, during the 90-day follow up, 69 (43%) patients 
died: in STE group 44 (47%), in STDEP 17 (42%) and in NSTD 8 (33 %) (p = 
0.31) (Figure 7C) ST-segment patterns did not associate with outcome in 
multivariable mortality analysis (Table 10B). 
 
Table 11 Angiographic features in the ACS subgroup 
 
 
Data presented as counts (percentages). * Percentages in patients with coronary 
angiography performed. Abbreviations: ACS = acute coronary syndrome, LM = left 
main, TIMI = Thrombolysis in Myocardial Infarction 
ACS Subgroup, 159 STE, 94 STDEP, 41 NSTD, 24 p 
Coronary angiography 
performed (%) 
91 (97) 38 (93) 21 (88) 0.22 
Three-vessel disease (%) 22 (24*) 16 (42*) 7 (35*) 0.12 
LM stenosis (%) 17 (19*) 9 (24*) 1 (5*) 0.15 
PCI (%) 84 (92*) 33 (87*) 18 (86*) 0.51 
TIMI 3 post-PCI (%) 59 (69*) 24 (75*) 15 (83*) 0.43 
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5.2 Ventricular conduction blocks in cardiogenic shock (II) 
5.2.1 Prevalence of ventricular conduction blocks in baseline ECG 
Study II included 199 ACS-related CS patients, of whom 155 patients were 
from the CardShock cohort and 44 from the Brno University CS study. Mean 
age was 66 ± 11 years, and 75% were men. 
Ventricular conduction block was present in half of the patients; 8 had 
LBBB, and 10 had isolated RBBB. Concomitant RBBB and hemiblock was 
present in 18 patients (8 with RBBB + LAHB, and 8 with RBBB + LPHB). An 
isolated hemiblock occurred in 32 patients (25 with LAHB and 7 with LPHB) 
and IVCD in 32 (Figure 8). In 72 patients from Helsinki, Barcelona and Brno, 
previous ECGs were sought for retrospectively, and the previous ECG was 
found in 30 (42%). 
 Overall, patients with ventricular conduction block were older and had 
lower LVEF than patients with normal ventricular conduction (Table 12). 
 
 
 
 
Figure 8 Prevalence of ventricular conduction blocks in ACS-related CS. 
Abbreviations: IVCD = unspecified intraventricular conduction delay, 
LBBB = left bundle branch block, RBBB = right bundle branch block, 
VCB = ventricular conduction block. Reproduced with publishers 
permission from Study II (256). 
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Table 12 Baseline characteristic of Study II patients. 
 
Data presented as counts (percentages), means ± SD or medians (IQR).  
*p < 0.05 when compared to patients with no ventricular conduction block (VCB). 
Abbreviations: BMP = beats per minute, eGFR= estimated glomerular filtration rate, 
hs-TnT = high-sensitive troponin T, IVCD = unspecified intraventricular conduction 
delay, LBBB = left bundle branch block, LM = left main , LVEF = left ventricular 
ejection fraction, NT-proBNP = N-terminal pro-natriuretic peptide, PCI = 
percutaneous coronary intervention, RBBB = right bundle branch block, SBP = 
systolic blood pressure, TIMI = Thrombolysis in Myocardial Infarction, VCB = 
ventricular conduction block 
 
No VCB 
(n = 99) 
Any VCB 
(n = 100) 
LBBB 
(n = 8) 
RBBB 
(n = 10) 
RBBB + 
hemiblock 
(n = 18) 
Hemiblock 
(n = 32) 
IVCD 
(n = 32) 
p 
Age, years 65 ± 11 69  ±  11* 75  ±  6* 72 ± 11 65 ± 12 70  ±  12* 67 ± 11 0.010 
Men (%) 73 (74) 77 (77) 5 (63) 6 (60) 17 (94) 22 (69) 27 (84) 0.67 
Diabetes mellitus 
(%) 
27 (27) 39 (39) 5 (63)* 5 (50) 4 (22) 11 (34) 14 (44) 0.13 
Coronary artery 
disease (%) 
28 (28) 34 (34) 5 (63)* 3 (20) 6 (33) 7 (22) 13 (41) 0.24 
Previous 
myocardial 
infarction (%) 
23 (23) 22 (22) 4 (50) 2 (20) 4 (22) 5 (16) 7 (22) 0.49 
Chronic heart 
failure (%) 
6 (8) 8 (10) 2 (40)* 1 (17) 2 (14) 1 (3) 2 (7) 0.16 
SBP, mmHg 80  
(70–90) 
80  
(70–89) 
85  
(64–114) 
78 (60–
108) 
80  
(70–88) 
80  
(74–85) 
80  
(70–86) 
0.94 
Heart rate, BPM 87  
(68–110) 
93 
(73–110) 
89  
(59–116) 
92 (68–
110) 
87  
(54–102) 
99  
(82–111) 
91  
(75–110) 
0.85 
LVEF, % 38 ± 14 33  ±  14* 26 ± 16 47 ± 15 30 ± 12 31 ± 14 34 ± 13 0.006 
Lactate, mmol/L 2.5 (1.5–
5.1) 
3.3 (2.2–
7.0)* 
3.4  
(3.1–3.7) 
8.5 (4.2–
13.3)* 
2.7  
(1.9–7.6) 
4.1 
(2.6–7.6)* 
2.4 (1.6–
4.9) 
0.002 
eGFR, 
ml/min/1.73 m2 
67 ± 29 57  ±  27* 50 ± 20 49 ± 24 62 ± 24 53 ± 24 63 ± 32 0.073 
Peak hs-TnT, ng/L 5801 
(3677–
12628) 
9293 
(2224–
22356) 
1747 
(763–
27762) 
423 
(31–
15503) 
16963 
(3656–
43742) 
16547 
(6407–
29879) 
4763 
(1912–
11913) 
0.015 
Peak NT-ProBNP, 
ng/L 
4544 
(2013–
9212) 
9053 
(3831–
23651)* 
18362 
(7222–
25733) 
8033 
(199–
14711) 
7200 (3775–
12214) 
17256 
(4826–
30617)* 
6164 
(2109–
16547) 
0.002 
Three-vessel 
disease 
35 (37) 26 (29) 4 (67) 3 (43) 4 (24) 9 (29) 6 (21) 0.23 
LM stenosis (%) 9 (10) 22 (24)* 1 (17) 0 (0) 4 (24) 11 (34)* 6 (21) 0.023 
TIMI 3 post-PCI 
(%) 
67 (80) 57 (67) 5 (83) 6 (75) 12 (71) 19 (66) 15 (60) 0.38 
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5.2.2 Temporal evolution of ventricular conduction blocks 
Temporal evolution of ventricular conduction blocks was assessed on day 3. 
Within the first three days, 32 (16%) patients died and were excluded from 
this analysis. Of the patients alive on day 3, 134 (80%) patients had ECG 
recorded. 
Sixty (45%) patients had no conduction block either at baseline or at 
day-3 ECG (= no block). Persistent block was present in 33 (25%) (the same 
type of block in baseline and in day-3 ECG). Transient block appeared in 26 
(19%) (the block present at baseline had disappeared at day 3). In 10 patients, 
the block present in baseline ECG had changed to another type of block, and 
5 patients without a block in baseline ECG had a newly appearing block in day 
3 ECG (Table 13). 
 
Table 13 Temporal evolution from baseline to day 3 of the ventricular 
conduction blocks (VCB). 
  
No 
block 
Block 
stayed 
Block 
disappeared = 
transient block 
Block 
changed 
Block 
appeared 
No VCB (%) 60 (92) 0 0 0 5 (8) 
LBBB (%) 0 5 (83) 0 1 (17) 0 
RBBB (%) 0 5 (83) 1 (17) 0 0 
RBBB + hemiblock (%) 0 6 (38) 6 (38) 4 (25) 0 
Hemiblock (%) 0 10 (56) 7 (39) 1 (6) 0 
IVCD (%) 0 7 (30) 12 (52) 4 (17) 0 
Total (%) 60 (45) 33 (25) 26 (19) 10 (8) 5 (4) 
 
Data presented as counts (percentages). Abbreviations: IVCD = unspecified 
intraventricular conduction delay, LBBB = left bundle branch block, RBBB = right 
bundle branch block, VCB = ventricular conduction block 
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5.2.3 Association of ventricular conduction blocks and mortality 
Patients with any ventricular conduction block had two-fold higher mortality 
than did patients with normal ventricular conduction (68% vs. 32%; p < 0.001, 
Figure 9). 
 
 
 
 
Figure 9 One-year Kaplan Meier curve in patients with any ventricular 
conduction block (VCB) or with normal ventricular conduction. 
Reproduced with publishers permission from Study II (256). 
 
Adjusted mortality analysis used two multivariable models. The first 
multivariable model included the following significant baseline covariates: 
age, gender, history of hyperlipidaemia, chronic obstructive pulmonary 
disease, previous PCI or CABG, SBP, LVEF, and eGFR. The second 
multivariable model included angiographic findings and it included three-
vessel disease, infarct-related artery, and TIMI 3 post-PCI. 
Any ventricular conduction block was associated with one-year 
mortality when adjusted with baseline covariates (HR 2.0, 95% CI 1.2 to 3.2; 
p = 0.004) or with coronary angiographic findings (HR 2.0, 95% CI 1.2 to 3.2; 
p = 0.006). When each ventricular conduction block was studied separately, 
each ventricular conduction block at least tended to associate with one-year 
mortality (p < 0.10) in the two multivariable models, except for IVCD when 
adjusted for previously described coronary angiogram findings (Figure 10).  
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Figure 10 Forest box plot for one-year mortality in patients with different 
ventricular conduction blocks. Abbreviations: IVCD = unspecified 
intraventricular conduction delay, LBBB = left bundle branch block, 
RBBB = right bundle branch block, VCB = ventricular conduction block. 
Reproduced with publishers permission from Study II (256). 
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Regarding temporal evolution of the blocks, one-year mortality was highest 
(18, 69%) in patients with transient block (Figure 11). In multivariable 
analysis, transient block was associated with one-year mortality when 
adjusted with baseline covariates (HR 4.4, 95% CI 2.0 to 9.6; p < 0.001) or 
with coronary angiography findings (HR 4.6, 95% CI 2.0 to 10.6; p < 0.001). 
 
 
 
 
 
Figure 11 One-year Kaplan Meier curves in patients with different temporal 
evolution of ventricular conduction blocks. Block disappeared = 
transient block. Reproduced with publishers permission from Study II 
(256). 
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5.3 SYNTAX scores in STEMI-related cardiogenic shock (III) 
5.3.1 SYNTAX scores and angiographic findings 
Study III included 61 patients with STEMI-related CS. Mean age was 67 ± 12 
years and 85% were men. At baseline, median baseline SYNTAX score 1 was 
22 (15–32). After wiring or thrombectomy, median baseline SYNTAX score 2 
was 19 (11–30), significantly lower than the baseline SYNTAX score 1 (p < 
0.01). After revascularization, median residual SYNTAX score was 7 (0–13), 
lower than SYNTAX score 1 and 2 (both p < 0.01).  
Patients were divided into tertiles by the baseline SYNTAX score 1 
value: the first tertile: ≤ 18 points, the second tertile: 19–27 points, and the 
third tertile: > 27 points. No differences appeared among the tertiles in age, 
gender, or most in comorbidities. Only the history of PCI was less common in 
the first tertile than in the second and third tertiles (n = 0, vs. n = 3 (15%) and 
n = 6 (30%), both p < 0.05). 
Table 14 describes the baseline characteristics and angiographic 
features of the Study III patients. Complete revascularization (residual 
SYNTAX score 0) was achieved more often in the first (57%) and second (25%) 
tertiles than in the third tertile, in which none of the patients reached complete 
revascularization (both p < 0.01). Overall, residual SYNTAX score was lower 
in the first and the second tertiles in comparison with the third tertile (both p 
< 0.01). More than half of patients (36, 59%) had shock before PCI, but with 
no difference in either SYNTAX score whether the patient had shock before or 
after the procedure (Table 15). 
For analysis of interobserver variability, Cohen’s Kappa statistics was 
0.59 (95% CI 0.40 to 0.78; p < 0.01) for baseline SYNTAX score and 0.65 (95% 
CI 0.32 to 0.97; p < 0.001) for residual SYNTAX score. 
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Table 14 Baseline characteristics and angiographic findings of Study III patients 
 
    First tertile 
 ≤ 18 points 
 n = 21 
Second tertile  
19-27 points 
n = 20 
Third tertile  
> 27 points 
n = 20 
p 
Age, years 62 ± 12 68 ± 13 70 ± 12 0.92 
Male gender (%) 20 (95) 14 (70) 18 (90) 0.06 
Coronary artery disease (%) 2 (10) 4 (20) 7 (35) 0.13 
Previous PCI (%) 0 (0) 3 (15) 6 (30) <0.01 
LVEF, % 37 ± 15 34 ± 14 29 ± 9 0.17 
SBP, mmHg 77 ± 23 77 ± 11 76 ± 12 0.98 
Serum lactate, mmol/l 2.2 (1.2-3.2) 2.3 (1.7-6.3) 2.8 (2.1-4.4) 0.31 
eGFR, ml/min/1.73m2 88 (65-104) 78 (42-98) 67 (41-87) 0.15 
hs-TnT, ng/l 2427  
(849-6810) 
7236  
(3677-11943) 
2889  
(1828-8965) 
0.04 
NT-proBNP, ng/l 198  
(133-942) 
1471  
(253-3977) 
3914  
(481-16551) 
<0.01 
Acute occlusive thrombosis (%) 12 (57) 15 (75) 12 (60) 0.45 
Chronic total occlusion (%) 1 (4.8) 1 (5.0) 15 (75) <0.01 
One-vessel disease (%) 14 (67) 8 (42) 0 (0) <0.01 
Three-vessel disease (%) 1 (4.8) 2 (11) 11 (55) <0.01 
Multivessel disease (%) 7 (33) 11 (55) 20 (100) <0.01 
LM disease (%) 3 (14) 3 (16) 3 (15) 0.99 
CS before angiography (%) 12 (57) 13 (65) 11 (55) 0.79 
Time from shock to 
angiography, min  
68 (23-112) 40 (15-86) 75 (15-90) 0.57 
Time from angiography to 
shock, min  
180 (60-300) 20 (15-75) 98 (45-175) 0.47 
Multivessel PCI (%) 4 (19) 6 (30) 7 (35) 0.5 
Residual SYNTAX score, pts  0 (0-5) 6 (1.0-10) 20 (10-28) <0.01 
Complete revascularization (%) 12 (57) 5 (25) 0 (0) <0.01 
TIMI 3 post-PCI (%) 14 (67) 12 (60) 14 (74) 0.66 
IABP (%) 10 (48) 14 (70) 13 (65) 0.31 
 
Data presented as counts (percentages), means ± SD or medians (IQR). 
Abbreviations: CS = cardiogenic shock, eGFR= estimated glomerular filtration rate, 
hs-TnT = high-sensitive troponin T, IABP = intra-aortic balloon pump, LM = left main, 
LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-natriuretic 
peptide, PCI = percutaneous coronary intervention, SBP = systolic blood pressure, 
TIMI = Thrombolysis in Myocardial Infarction 
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Table 15 Baseline and residual SYNTAX scores in patients who developed shock 
before or after PCI. 
  
CS before 
revascularization, 
36 
CS after 
revascularization, 
25 
p 
Baseline SYNTAX score, 
pts 
22 (15-22) 22 (15-31) 0.84 
Residual SYNTAX score, 
pts 
7 (0-18) 6 (0-11) 0.56 
 
Data presented as medians (IQR). Abbreviations: CS = cardiogenic shock 
 
5.3.2 Prognostic value of SYNTAX scores 
In 90-day follow-up, 26 (43%) patients died. In the first tertile, 90-day 
mortality rate was lowest (4, 19%,), and mortality was higher in the second 
(10, 50%) and the third tertiles (12, 60%) (p = 0.02, Figure 12A). Use of 
different residual SYNTAX score cutoff points (0, 8, or 12 points) produced no 
significant differences in 90-day mortality (Figure 12B-D). 
Of the four multivariable models created, the first multivariable model 
included significant baseline covariates: age, LVEF, arterial blood lactate, 
eGFR, NT-proBNP, and TIMI 3 post-PCI. The other three models included 
baseline or residual SYNTAX score and either CardShock risk score (85), 
IABP-SHOCK II risk score (84), or GRACE risk score (82).  
 In multivariable analysis, baseline SYNTAX score was associated with 
mortality in adjusted analysis with covariates and the IABP-SHOCK II and 
GRACE risk scores, but not when adjusted for the CardShock risk score (Table 
16A). Residual SYNTAX score as a continuous or a categorical variable was 
not associated with 90-day mortality in adjusted analyses (Table 16B).  
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Figure 12 90-day Kaplan-Meier survival curves in baseline SYNTAX score tertiles 
(2a) and in different residual SYNTAX score (rSS) cutoff points (2b-d). 
Reproduced with publisher’s permission from Study III (257). 
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Table 16 Multivariable mortality analysis with (A) baseline SYNTAX score and 
(B) residual SYNTAX score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a per increase of 1 point.  
b control variables: age, LVEF, arterial blood lactate, eGFR, NT-proBNP and TIMI 3 
post-PCI 
Abbreviations: bSS = baseline SYNTAX score, eGFR= estimated glomerular filtration 
rate, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-natriuretic 
peptide, rSS = residual SYNTAX score, TIMI = Thrombolysis in Myocardial Infarction 
 
  
A)  HR 95% CI p 
bSSa + control variablesb 1.06 1.01-1.10 0.03 
bSSa + CardShock risk score 1.02 0.98-1.06 0.29 
bSSa + IAPB-SHOCK II risk score 1.05 1.01-1.09 <0.01 
bSSa + GRACE risk score 1.04 1.00-1.08 0.04 
B) 
   
rSSa (continuous) + control variablesb 1.03 0.99-1.08 0.14 
rSSa (continuous) + CardShock risk score 1.02 0.98-1.06 0.44 
rSSa (continuous) + IAPB-SHOCK II risk 
score 
1.03 0.99-1.07 0.08 
rSSa (continuous) + GRACE risk score 1.03 0.99-1.07 0.11 
    
rSS>0 + control variablesb 2.46 0.83-7.29 0.11 
rSS>0 + CardShock risk score 2.41 0.80-7.26 0.12 
rSS>0 + IAPB-SHOCK II risk score 2.05 0.70-6.00 0.19 
rSS>0 + GRACE risk score 1.83 0.62-5.43 0.28 
    
rSS≥8 + control variablesb 1.27 0.55-2.94 0.58 
rSS≥8 + CardShock risk score 1.05 0.48-2.31 0.91 
rSS≥8 + IAPB-SHOCK II risk score 1.36 0.62-2.99 0.45 
rSS≥8 + GRACE risk score 1.44 0.67-3.11 0.36 
    
rSS≥12 + control variablesb 1.54 0.65-3.66 0.33 
rSS≥12 + CardShock risk score 1.26 0.55-2.88 0.58 
rSS≥12 + IAPB-SHOCK II risk score 1.53 0.67-3.49 0.31 
rSS≥12 + GRACE risk score 1.71 0.77-3.80 0.19 
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For evaluation of risk assessment, the AUC of the baseline SYNTAX score 1 
was 0.68 (95% CI 0.55 to 0.80), and the AUC of the residual SYNTAX score 
was 0.62 (0.48 to 0.74). The CardShock risk score had the highest AUC, 0.80 
(95% CI 0.67 to 0.89) (Figure 13). 
  
 
Figure 13 ROCs and AUCs of the SYNTAX scores and the studied risk scores. 
Abbreviations: AUC = area under the curve, bSS = baseline SYNTAX 
score, ROC = receiver operating characteristic, rSS = residual SYNTAX 
score. Reproduced with publisher’s permission from Study III (257). 
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5.4 Angiographic features in cardiogenic shock (IV) 
5.4.1 Angiographic findings and procedural characteristics 
Study IV included 158 CardShock patients with ACS-related CS. Median age 
was 67 ± 11 years, and 77% were men. One-vessel disease was the finding in 
49 (31%) patients, two-vessel disease in 59 (37%), and three-vessel disease in 
50 (32%). The most common IRA was LAD in 63 (40%) patients, followed by 
RCA in 48 (31%). LM as the IRA appeared in 19 (12%) (Figure 14). 
 
 
 
Figure 14 Prevalence of infarct-related arteries. Abbreviations: LAD = left 
anterior descending coronary artery, LCX = left circumflex coronary 
artery, LM = left main coronary artery, RCA = right coronary artery, 
SVG = saphenous vein graft 
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SVG
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Almost all patients were treated with PCI (91%), and only eight patients were 
treated with CABG (9%) (Table 17). Successful revascularisation (TIMI 3 post-
PCI) was achieved in 102 (72%). No difference in rate of successful 
revascularization emerged between the different IRAs (Figure 15). In 
addition, revascularization of the IRA was analysed between patients who 
developed shock before (n = 95) or after PCI (n = 49), and no difference was 
found in TIMI 3 flow post-PCI (68 % vs. 78 %; p = 0.31). 
 
Table 17 Procedural characteristics of percutaneous coronary intervention 
 
 
Data presented as counts (percentages) or medians (IQR). 
Abbreviations: LM = left main, PCI = percutaneous coronary intervention, TIMI = 
thrombolysis in myocardial infarction 
 
 
Procedural characteristics All PCI treated 
patients, 
144 
Survivors, 
82 
Non-
survivors,  
62 
p 
Symptom-to-balloon time, min 340 (196-660) 335 (210-
641) 
340 (190-
660) 
0.70 
Number of stents (%)    0.51 
1 89 (65) 55 (69) 34 (60)  
2 32 (23) 18 (23) 14 (25)  
>3 10 (7) 5 (6) 5 (9)  
Bare metal stent (%) 66 (46) 39 (48) 27 (44) 0.76 
Multivessel PCI (%) 38 (26) 21 (26) 17 (27) 0.96 
PCI of LM (%) 21 (15) 8 (10) 13 (21) 0.11 
Total occlusion (pre-PCI TIMI 
0/1) (%) 
119 (84) 65 (80) 54 (89) 0.27 
TIMI post-PCI (%)    0.03 
0/1 15 (11) 6 (7) 9 (15)  
2 25 (18) 10 (12) 15 (25)  
3 102 (72) 66 (81) 36 (60)  
Amount of contrast agent, ml 160 (120-220) 170 (120-
210) 
160 (124-
250) 
0.66 
Shock after PCI (%) 49 (36) 33 (41)           16 (28)              0.16 
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Figure 15  Percentages of patients who had TIMI 3 flow post-PCI. Abbreviations: 
LAD = left anterior descending coronary artery, LCX = left circumflex 
coronary artery, LM = left main coronary artery, PCI = percutaneous 
coronary intervention, RCA = right coronary artery, SVG = saphenous 
vein graft 
5.4.2 Prognostic effect of angiographic features and procedural success 
Patients with one-vessel coronary artery disease had the lowest 90-day 
mortality rate; the mortality rate was higher in patients with two- or three-
vessel coronary artery disease (25% vs. 48% vs. 52%; p = 0.018; Figure 16A). 
Mortality was numerically higher if the IRA was the LM (53%) or the LAD 
(48%) when compared to mortality with the IRA being the RCA (29%) or the 
LCX (24%) (Figure 16B). Successful revascularization of the IRA, i.e. TIMI 3 
post-PCI, was achieved more often in survivors than in non-survivors (81% 
vs. 60%; p = 0.019, Table 17, Figure 16C). 
In multivariable Cox regression analysis, multivessel coronary artery 
disease (HR 2.59, CI 95% 1.29 to 5.18; p = 0.007), TIMI flow < 3 post-PCI 
(HR 2.41, CI95% 1.4 to 4.15; p = 0.001), increasing lactate (HR 1.17, CI95% 
1.11 to 1.23; p<0.001), and decreasing LVEF (HR 1.03, CI95% 1.01 to 1.06; 
p = 0.002) were independently associated with 90-day mortality. 
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Figure 16 90-day Kaplan-Meier curves in patients with (A) different numbers of 
diseased coronary arteries, with (B) different IRAs and with (C) 
different TIMI-flow grades post-PCI. Abbreviations: LAD = left anterior 
descending coronary artery, LCX = left circumflex coronary artery, LM 
= left main coronary artery, RCA = right coronary artery, SVG = 
saphenous vein graft, TIMI = thrombolysis in myocardial infarction 
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5.4.3 Complications of percutaneous coronary intervention 
Of the patients, one-third, 51 (35%) had a procedural complication, with no 
difference in rate of procedural complications between survivors and non-
survivors (31% vs. 42%; p = 0.21). Most of the complications were arrhythmic: 
19% had ventricular tachycardia or fibrillation, and 15% had bradycardia. 
Bradycardia was more frequent in non-survivors than in survivors (23% vs 
9%; p = 0.034), but it was not associated with risk of 90-day death in adjusted 
analysis (HR 1.09, 95% CI 0.51 to 2.35; p = 0.82) (Table 18). 
 
 
Table 18 Complications of percutaneous coronary intervention (PCI) 
 
 
Data presented as counts (percentages). 
PCI Complications All PCI treated 
patients, 144 
Survivors, 
82 
Non-survivors, 
62 
p 
Any PCI complication (%) 51 (35) 25 (31) 26 (42) 0.21 
Ventricular tachycardia or 
fibrillation (%) 
27 (19) 11 (13) 16 (26) 0.10 
Bradycardia (%) 21 (15) 7 (9) 14 (23) 0.034 
Dissection (%) 8 (6) 5 (6) 3 (5) 1.00 
Tamponade (%) 1 (1) 1 (1) 0 (0) 1.00 
Re-occlusion (%) 4 (3) 1 (1) 3 (5) 0.43 
Re-coronary angiography (%) 12 (9) 10 (13) 2 (3) 0.10 
Re-PCI (%) 10 (7) 8 (10) 2 (3) 0.22 
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6 DISCUSSION 
6.1 ST-segment deviations in cardiogenic shock 
6.1.1 ST-segment deviations, CS aetiology, and patient characteristics 
In Study I, the majority of CS patients with various CS aetiologies had ST-
segment deviations in their baseline ECG. STE was the most common finding 
in half the patients, with STDEP being found in approximately one-third of 
these patients. In overall CS, the prevalence of ST-segment deviations has not 
been studied.  In ACS, CS incidence has been two to three times higher in 
STEMI than in NSTEMI (11,60,62,210). 
The high prevalence of ST-segment deviations reflects primarily the 
high prevalence of ACS aetiology in our Study I population. Especially in ACS 
patients, the higher prevalence of STE than of STDEP may be associated with 
different pathophysiologic mechanisms of ST-segment changes in the 
ischaemic setting. STE often results from total occlusion of the IRA (129), 
leading to transmural ischaemia (193) and to large areas of ischaemic 
myocardium, which is also supported by our finding of  high troponin values 
in STE patients. STDEP, on the other hand, is more often the result of  partial 
occlusion of the culprit artery and subendocardial ischaemia (205). In 
addition, as earlier evident in NSTEMI, two-thirds of the occluded culprit 
arteries already have collateral circulation (258,259), suggesting that in many 
cases the occlusion has an earlier origin. One may hypothesize that the 
collaterals often found in NSTEMI could protect against development of CS, 
which may explain the higher prevalence of STE in CS than in STDEP. 
Of the studied ST-segment patterns, in particular STE was associated 
with ACS aetiology. CS was the first manifestation of heart disease in the 
majority of STE patients, nearly all of whom had ACS, and smoking was an 
important factor. The second most common CS aetiology was exacerbation of 
chronic heart failure, in which the cause of STE may be ischaemic 
cardiomyopathy caused by previous myocardial infarction with extensive 
scarring and chronically elevated ST-segment levels. Other causes of CS were 
valvular dysfunction and myocarditis, but interestingly, none of our patients 
with stress-induced cardiomyopathy had STE. The most common localisation 
of STE was anterior in half of our patients, suggesting the occlusion of the  LAD 
(201). 
Roughly one-third of our patients with STDEP had no ACS. Patients 
with STDEP were in their old age and had a high prevalence of previous 
diagnoses of coronary artery disease, chronic heart failure, and atrial 
fibrillation. Hence, the second most common aetiology in this group was 
exacerbation of chronic heart failure, followed by valvular dysfunction, 
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myocarditis, and stress-induced cardiomyopathy. In patients with aetiology 
other than ACS, the cause of STDEP may have been secondary ischaemia due 
to an imbalance between oxygen supply and demand, for example in patients 
with severely low blood pressure (48). Thus, in CS patients, STE implies most 
straightforwardly ACS, while in patients with STDEP, other aetiologies must 
be considered. 
In patients without ST-segment deviation, ACS was still the main cause 
of CS in two-thirds of the patients. The other causes were exacerbation of 
chronic heart failure in roughly one-third, followed by stress-induced 
cardiomyopathy and by myocarditis. This reminds us that in CS, ACS is the 
most common cause, even though no ST-segment deviations are visible in the 
ECG. 
6.1.2 Prognostic effect of ST-segment deviations 
We studied mortality rates in the entire patient cohort with its various CS 
aetiologies, and separately studied the subgroup with ACS aetiology. In the 
entire study cohort, STE was associated with higher mortality than were other 
ST-segment patterns. This finding most likely is associated with the fact that 
STE occurred almost only in patients with ACS aetiology, and those with ACS 
tended to suffer from higher mortality rates than did patients with other CS 
aetiologies. No other study, to our knowledge, has reported mortality rates 
related to ST-segment patterns in patients with unselected CS aetiology. 
In the ACS subgroup, no difference emerged in survival rates between 
patients with differing ST-segment patterns. Generally, in ACS, STEMI proves 
to be related to a higher in-hospital mortality rate than does NSTEMI, but 
their long-term prognoses are similar (260–264). Mortality rates for STEMI 
and NSTEMI in CS are controversial. Three CS studies reported NSTEMI 
patients to have higher mortality than do STEMI patients (60,62,210), but two  
other studies found no difference in survival (11,211). Comparing the 
differences between earlier CS studies and ours shows that in our study, the 
rates of coronary angiography (91%) and PCI (82%) in NSTEMI patients were 
higher than were earlier rates of coronary angiography ranging between 41% 
and 72% and PCI 13% and 72% (62,135,210,211). Furthermore, we found no 
difference in rates of coronary angiography and PCI between STEMI and 
NSTEMI patients, whereas other studies have reported significantly lower 
rates of invasive treatment in NSTEMI than in STEMI (60,62,210,211). It is 
thus possible that our extensive rate of revascularisation in NSTEMI patients 
was associated with better survival, which resulted in similar mortality rates 
as in STEMI. This finding highlights the importance of emergent coronary 
angiography and PCI for all ACS-related CS patients, regardless of ST-segment 
pattern. 
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6.2 Ventricular conduction blocks in cardiogenic shock 
6.2.1 Prevalence of ventricular conduction blocks 
In Study II, the prevalence of any ventricular conduction disturbance in 
baseline ECG was high, because half the patients had a ventricular conduction 
disturbance. The most prevalent findings were IVCD and isolated hemiblocks, 
both in 16% of the patients, followed by RBBB + hemiblock in 9%, isolated 
RBBB in 5%, and LBBB in 4%. Earlier CS findings showed a prevalence of 
RBBB from 13% to 20% and of LBBB from 2% to 10%, values thus similar to 
ours (11,20,209). The high prevalence of hemiblocks, isolated or associated 
with RBBB, was an interesting finding, as they have not been studied in the 
context of ACS-related CS before. Overall, in ACS patients, the prevalence of 
RBBB has been somewhat lower, but the prevalence of LBBB has been similar 
(13–16). Like our results, the incidence of LAHB in ACS has been estimated 
at 7% to 15% (265–268). 
6.2.2 Association of ventricular conduction with patient characteristics  
We found that patients with any ventricular conduction disturbance, when 
compared to patients with normal ventricular conduction, were older, had 
lower LVEF, higher troponin levels, and had the LM coronary artery more 
often as the IRA. Patients with RBBB + hemiblock had an especially high risk 
profile, as they had a low LVEF of 30%, high troponin levels, and the LM as 
the IRA in 18%. In contrast, in patients with isolated RBBB, LVEF was only 
moderately lowered at 47%, levels of troponin were lower, and none had the 
LM as the IRA. Patients with LBBB were older and had a high prevalence of 
chronic heart failure and coronary artery disease and a low ejection fraction. 
Similar to our results, in ACS-related CS, both LBBB and RBBB have been 
associated with lower ejection fraction, higher prevalence of comorbidities, 
and a higher rate of the LM as the IRA (11). Furthermore, in one 
contemporary study, those patients with RBBB + hemiblock rather than 
isolated RBBB were older, had a higher prevalence of comorbidities and  a 
lower ejection fraction, and more often had three-vessel disease and the LAD 
as their  IRA (13).  
6.2.3 Temporal evolution of ventricular conduction blocks 
In Study II, among those patients who showed a ventricular conduction block 
at baseline, one-fourth of the blocks reversed, and 10% changed into another 
block. None of the transient blocks were present in the patients’ previous 
ECGs, suggesting that the blocks resulted from acute myocardial ischaemia 
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(17,18,222). Many of the transient blocks were hemiblocks associated with or 
without RBBB, which may result from slowed myocardial conduction leading 
to an axis deviation comparable to hemiblock, a phenomenon that may 
corrected by appropriate revascularization (9,222,228). The temporal 
evolution of conduction blocks has not been evaluated in CS, but in ACS, the 
rate of new-onset block reversion has been reported as high as 49% to 77% 
(16,19), similar to our findings. The block reversion rate was lowest in patients 
with RBBB and LBBB, implying that many of these changes may be of earlier 
origin.  
6.2.4 Prognostic value of ventricular conduction blocks 
We discovered that patients with any ventricular conduction block had two-
fold higher mortality in than did patients with normal ventricular conduction. 
This result may be in part explained by the fact that changes in QRS duration 
and morphology reflect critical myocardial ischaemia (9,229), which 
subsequently may predict a poor prognosis. Even though the patients with 
ventricular conduction blocks were older, with more comorbidities and more 
severe coronary artery disease, the association with mortality was 
independent of baseline and clinical characteristics, as well as of the findings 
of coronary angiography and the success of revascularization.  
When we examined ventricular conduction blocks separately, 
especially RBBB + hemiblock and isolated hemiblocks were independently 
associated with mortality. In addition, LBBB and isolated RBBB tended to be 
associated with mortality. In one study of ACS-related CS, RBBB was 
associated with worse survival in than was STEMI, but that study did not cover 
hemiblocks (11). Our study is thus, to our knowledge, the first to show the 
association of hemiblocks and mortality in CS patients. In overall ACS, the 
negative prognostic impact of ventricular conduction blocks has been evident 
(11,12,14–16).  
 In addition, we evaluated the association of temporal block evolution 
and mortality. Mortality was highest in patients with transient block, a result 
conflicting with earlier ACS findings (12,16). We hypothesised that the 
explanation for this difference consists of multiple factors. Many of the 
transient blocks we recorded were of new origin, which has been associated 
with poor prognosis in ACS (13,14,16). Secondly, the reversal of ventricular 
conduction disturbances has been thought to associate with restoration of 
coronary circulation (20), which in general in ACS is a good sign.  However, in 
CS, because the state of shock has already developed, factors other than 
successful revascularization will contribute to mortality, such as 
haemodynamic instability and multiorgan failure; therefore, reversion of the 
block may lack the same effect as in general in ACS. In addition, the excess 
mortality in patients with reversible block did not only consist of early 
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mortality, but also of later deaths, suggesting mechanisms of mortality other 
than acute haemodynamic instability. Indeed, patients with transient block 
had the highest troponin values, indicating major myocardial damage and 
thus possible scarring, which in turn may have predisposed to arrhythmic 
events and sudden cardiac death. 
6.3 Angiographic features in cardiogenic shock 
6.3.1 Features of coronary artery disease 
We found that the majority of patients with ACS-related CS had complex 
coronary artery disease (III and IV). In Study IV, one-third of the patients had 
two-vessel disease and one-third three-vessel disease. In STEMI-related CS 
(III), the prevalence of two-vessel disease was higher at 40% and three-vessel 
disease lower at 23%. Our finding of a high prevalence of multivessel disease 
is in accordance with other CS study findings, even though our prevalence of 
three-vessel disease was slightly lower than described (25,27,28,121,122). 
 In Study IV, LAD was the most common culprit artery in 40%, followed 
by RCA in 31%, LCX in 14%, LM in 12%, and saphenous vein graft (SVG) in 
3%, corresponding to previous findings (23,25,27). LAD as the predominant 
culprit artery in patients with CS is comprehensible, since LAD occlusion has 
been associated in STEMI with increased risk for de-novo heart failure (269), 
and anterior myocardial infarction has been associated with risk for CS in 
STEMI patients with multivessel disease (270). 
 In Study III, the median baseline SYNTAX score at baseline was 22 
(IQR 15-32) points, higher than previously described in CS (17 ± 10 points) 
(180), but the definition of CS in our study was stricter. The baseline SYNTAX 
score was also higher than in other studies with STEMI patients 
(36,37,175,177). Accordingly, earlier studies have shown that CS incidence 
was higher in STEMI patients with a high SYNTAX score (36,177) and that 
higher SYNTAX score was a predictor of CS in patients with acute myocardial 
infarction (180). 
6.3.2 Characteristics of percutaneous coronary intervention 
In Study IV, 91% of the CS patients with ACS aetiology underwent PCI 
procedure, which is similar to data in contemporary CS studies (24,28). IABP 
was utilized in 65% of our patients, reflecting the fact that results of the IABP-
SHOCK II trial were then unavailable, because the recruitment periods were 
overlapping (105). Multivessel PCI was performed in one-fourth of the 
patients, roughly corresponding to the rates in other studies (23,120,143).  
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Successful revascularization (TIMI 3 post-PCI) occurred in 72% of the 
patients, a similar rate as in the IABP-SHOCK trial (24), yet a distinctly lower 
rate than reported overall in STEMI or NSTEMI, with successful 
revascularization in over 90% (271,272). The reason for lower PCI success 
rates in CS than in overall ACS may be associated with the facts that patients 
with CS have more complex lesions and that haemodynamic instability may 
interfere with the challenging PCI procedure. However, no difference in the 
rate of successful revascularization emerged between the IRAs, a result similar 
to that of the IABP-SHOCK trial (24). A distinctive reduction from baseline to 
residual SYNTAX score appeared, which implies that revascularization 
improved coronary artery circulation as anticipated. However, the residual 
SYNTAX score was higher than earlier described in STEMI (37), and the rate 
of complete revascularization (residual SYNTAX score 0) was lower than in 
overall patients treated with PCI (181,183–185), which reflects the 
complexity of CS patients’ coronary artery disease. 
Nearly half the patients presented with shock only after PCI, in 
accordance with the fact that most patients develop shock only after hospital 
admission (1,10,60,61), and that urgent revascularization is a strong 
recommendation in STEMI (109). However, no difference arose in success of 
revascularization (measured as TIMI 3 post-PCI or residual SYNTAX score) 
between patients who developed CS before or after PCI. This suggests that the 
cause of CS was not failure of revascularization. Furthermore, most study 
patients who developed CS after revascularization did so during the first hours 
after angiography, suggesting that the pathophysiological CS changes had 
probably started even before coronary angiography. The delay from symptom 
onset to PCI treatment was surprisingly long, with a median time of 6 hours, 
but any data regarding patient-related delays or transfer times was 
unavailable. In addition, 11% received thrombolysis before revascularization, 
which may partly explain the longer treatment delay.  
6.3.3 Prognosis related to angiographic features and procedural success 
In Study IV, multivessel disease was associated with worse survival, as also 
shown elsewhere (22,23,25–28). In addition, baseline SYNTAX score was 
associated with mortality in adjusted analysis with clinical covariates, as well 
as when adjusted with GRACE or with IABP-SHOCK II risk scores. This is in 
line with previous findings in STEMI patients, in which baseline SYNTAX 
score was credited with a robust predictive value (34–36). In addition, in ACS, 
baseline SYNTAX score was useful in risk stratification beyond the GRACE 
risk score. (273). However, the additive value of baseline SYNTAX Score in 
our study was marginal, which compromises the benefit of SYNTAX Score 
calculation for risk evaluation in CS. In our opinion, the clinical risk scores are 
more feasible and clinically accurate in CS risk stratification; assessing the 
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exact burden of coronary artery disease with baseline SYNTAX score may thus 
not be a wise use of resources.  
We found that mortality was highest (100%) in patients with SVG as 
the IRA, followed by LM (53%), LAD (48%), RCA (29%), and LCX (24%). The 
dismal prognosis with SVG as the IRA may not only be associated with graft 
occlusion, but also with the comorbidities in a patient already treated with 
CABG. Overall, no statistically significant differences in outcome emerged 
between the different IRAs, a similar finding to that in a substudy of the IABP-
SHOCK II trial (24). In other CS studies, LM has been associated with poor 
outcomes (23,25,27,31), whereas RCA as the IRA has been associated with 
better survival (26,32). Instinctively, it seems credible that LM as the culprit 
artery could be linked to poor outcome. However, it may be hypothesized that 
the culprit vessel with the corresponding area at risk only plays minor role in 
CS survival, especially when revascularization is successful; mortality may be 
more strongly associated with systemic alterations and multiorgan damage. 
  Studies III and IV revealed that successful revascularization of 
the IRA (TIMI 3 post-PCI) was associated with better survival, as shown 
previously (23–25,27–31,121,122). However, regarding completeness of 
revascularization, no association with residual SYNTAX score and survival 
appeared, even though residual SYNTAX scores have predicted mortality in 
overall ACS patients (37–39). The difference between our study population 
and earlier ACS studies is that our patients were critically ill; thus, their 
prognosis is related more often to factors other than the completeness of 
revascularization. In critically ill CS patients, treatment goals must include not 
only successful revascularization but also management of haemodynamic 
stability, prevention of multiorgan dysfunction, and management of 
ventilation support. In this context, complicated PCI procedures targeting low 
residual SYNTAX score may even worsen a patient’s condition. Again, 
however, successful revascularization of the IRA was independently 
associated with better survival, which highlights the importance of restoring 
IRA blood flow, whereas aiming at complete revascularization may prove 
excessive. The message is similar to that of the CULPRIT-SHOCK trial, in 
which PCI treatment of the culprit lesion alone was associated with better 
outcomes than with multivessel PCI (151). 
In Study IV, the symptom-to-balloon time was rather prolonged, with 
a median delay of 6 hours. No difference appeared in symptom-to-balloon 
time between survivors and non-survivors, a similar finding as that of the 
SHOCK trial, in which shock-onset-to-balloon time was also prolonged at 5 
hours, with no association with shock-onset-to-balloon time and mortality 
(121). Others have, however, found that, in CS, shorter symptom-onset-to-
balloon time (25,138), shorter first medical contact-to-balloon (136,137) and 
shorter door-to-balloon (138) time were associated with better survival. One 
crucial difference between our study and these was that we also included 
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patients who developed CS only after PCI. That may explain the longer delay 
from symptom-to-balloon and may also be the reason that longer delay did 
not lead to significantly higher mortality. In addition, some of the patients 
were treated with thrombolysis, which could cause a longer delay from 
symptom to balloon, and in which case longer delay may not contribute to 
mortality. 
6.3.4 Procedural complications of percutaneous coronary intervention 
In Study IV, procedural complications occurred in one-third of the patients, 
the most common being arrhythmic complications. Ventricular tachycardia or 
fibrillation was discovered in 19% and bradycardia in 15%. Overall, the rate of 
procedural complications during PCI was higher than previously in STEMI 
(33), and also higher than in a registry study of ACS-related CS (31). One may 
hypothesize that most of the arrhythmic events relate to the severity of the 
acute cardiac illness, and not just to the revascularization procedure itself. 
Indeed, complications were not associated with mortality, suggesting that they 
were treatable and transient. In addition to arrhythmias provoked by the 
cardiac instability and the PCI procedure, reperfusion arrhythmias are also 
possible in ACS-related CS (274). As our results show a high prevalence of 
arrhythmic events during PCI, immediate action such as defibrillation and 
cardiac pacing should be readily available for management of arrhythmic 
complications. 
6.4 Limitations 
Some limitations in this thesis are apparent. Regarding Studies I and II, it is 
essential to acknowledge the dynamic nature of ECG. Especially in the context 
of ACS, the ECG, and especially the ST-segment pattern, could change within 
minutes if there occurred an alteration in myocardial ischaemia such as rapid 
reperfusion or new occlusion of the coronary artery. However, we believe that 
these studies with one analysed baseline ECG per patient reflects clinical 
practice, for ECG is only one part of decision-making in a critical situation, 
and ECG may not be repeated especially in the first busy moments of CS 
management. In Study II, another limitation was the lack of earlier ECGs in 
many study patients, even after our retrospective search. This reflects, 
however, real-life practice, as CS patients are most often referred to a tertiary 
care center, where their previous ECGs may be unavailable. In addition, due 
to high early mortality, the number of patients with serial ECGs in Study II 
was low. Still, Study II, to our knowledge, involved the largest cohort in an 
examination of serial ECGs in the context of CS. 
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In general, one important limitation of this study is its sample size. 
Even though this study’s sample was considerable for a prospective study of 
CS, the number of patients in some groups was low: around 20 patients in 
Study III. However, Study III was the first, and the largest study to analyse 
baseline and residual SYNTAX scores. Another limitation in Study III was that 
the interpretation of the angiograms was not centralized; rather, the SYNTAX 
scores were analysed in each hospital by one local experienced cardiologist. 
However, both were well trained to calculate the SYNTAX score, with no 
difference in interobserver agreement. Similarly, in Study IV, examination of 
the angiograms was not centralized, but the results were reported by the 
treating interventional cardiologists. 
6.5 Clinical implications and future directions 
This prospective CardShock study represents real-life CS patients with various 
CS aetiologies. Research in critically ill patients is challenging, which 
underlines the importance of multinational studies like the CardShock study.  
 We showed that, in CS, despite the development of more refined 
imagining techniques, ECG is still a useful tool in diagnostics and in 
assessment of prognosis.  As stated in the guidelines (109), ECG should be one 
of the first measurements in critically ill patients, as it provides us with 
valuable information on the causes of CS and its prognosis. We showed that 
evaluation of the ST-segment pattern is useful in diagnostics, as most of the 
STE patients have ACS as the cause of their CS. On the other hand, along with 
the findings of STDEP and NSTD, other causes for CS aetiology need 
consideration, with corresponding diagnostic efforts, such as prompt 
echocardiography. Nevertheless, urgent angiography should be essential in 
every CS patient regardless of ST-segment changes, because ACS is still the 
most common cause of CS in each patient group despite differing ST-segment 
patterns.   
In addition to ST-segment pattern, QRS configuration demands careful 
analysis, because ventricular conduction blocks, even hemiblocks, are 
associated with worse prognosis. The dismal prognosis of RBBB was recently 
acknowledged; the most recent European STEMI guideline included RBBB, 
along with LBBB, as the indication for urgent revascularization (109). The 
clinical value of IVCD and hemiblocks is still debatable, but our findings show 
that, their negative prognostic value should be recognised, with corresponding 
treatment efforts. Especially those CS patients with transient block face high 
mortality rates, which necessitates repeated ECG recordings during hospital 
stay and more intensive follow-up in those patients with an evolving QRS 
pattern. Interestingly, the mortality rates in patients with transient block were 
higher even after the early phase, which may have been associated with large 
infarctions leading to scarring and arrhythmic events. Thus, the finding of a 
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transient block may argue for more comprehensive analysis of myocardial 
damage, for example cardiac magnetic resonance imaging, and for more 
precise heart rhythm monitoring. 
 In CS patients with ACS, the mainstay of treatment is urgent coronary 
angiography and revascularization.  The patients with multivessel disease are 
at high mortality risk, which necessitates close-up monitoring and more active 
management. Crucial for improvement of outcome is successful 
revascularization of the IRA, even if the procedure is delayed. However, 
targeting immediate complete revascularization does not improve survival, a 
similar finding with the CULPRIT-SHOCK trial (151), also acknowledged in 
the updated guidelines of myocardial revascularization (87). Regrettably, the 
result of PCI in CS patients was not optimal, with the successful 
revascularization rate of the IRA being lower than recorded previously in ACS 
patients overall, an important finding to be addressed. Complications during 
the PCI procedure are common, with arrhythmias especially abundant. Any 
complications should be prevented, if possible, but the occurrence of a 
complication is not fatal, because the complications were treatable and not 
associated with increased mortality.  
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7 CONCLUSIONS 
The present thesis was designed to assess electrocardiographic and 
angiographic features in CS patients. ECG is an important tool for 
differentiating CS aetiology. In addition, ECG is useful in risk assessment, 
because STE and ventricular conduction blocks were markers of high 
mortality. In addition to ECG, some angiographic features may be useful in 
assessment of prognosis. Multivessel disease carried a high mortality risk, and 
successful revascularization of the IRA was associated with better outcome. 
Baseline ECG in patients with CS was distinctively aberrant, with a high 
prevalence of ST-segment deviations (I) and ventricular conduction 
disturbances (II). In CS patients with various aetiologies, STE was associated 
with ACS aetiology, but, surprisingly, one-third of the patients with STDEP 
had no ACS. However, STDEP was associated with a high burden of previously 
diagnosed coronary artery disease and other comorbidities (I). Like STDEP, 
ventricular conduction disturbances occurred more often found in older 
patients with a higher burden of comorbidities (II). 
In patients with various aetiologies, STE was associated with high 
mortality. In the subgroup of ACS-related CS, no difference in 
revascularization or mortality rates emerged among the ST-segment patterns 
(I). In ACS-related CS, any ventricular conduction disturbance on baseline 
ECG was associated with worse prognosis, but the later reversal of the block 
was not associated with better survival (II). 
In patients with ACS-related CS, complex coronary artery disease was 
extremely common (III and IV). In STEMI-related CS, high values of the 
baseline and residual SYNTAX score were frequent, but their additive value in 
risk prediction beyond clinical assessment and risk scores was marginal (III). 
Multivessel disease was associated with poor prognosis. The crucial 
prognostic factor proved to be successful revascularization of the IRA (TIMI 3 
post-PCI) (III and IV), and even delayed PCI seemed to be associated with 
better prognosis (IV). In ACS-related CS patients undergoing PCI, arrhythmic 
complications were common, but they were not associated with excess 
mortality (IV). 
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